



(51) International Patent Classification:

C07C 271/12 (2006.01) C07D 417/12 (2006.01)
C07C 271/16 (2006.01) C07C 309/73 (2006.01)
C07C 271/20 (2006.01) C07C 329/16 (2006.01)
C07D 203/20 (2006.01) A61K 31/426 (2006.01)
C07D 233/60 (2006.01) A61P 31/12 (2006.01)
C07D 277/24 (2006.01)

(21) International Application Number:

PCT/US2013/024431

(22) International Filing Date:

1 February 2013 (01.02.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/594,686 3 February 2012 (03.02.2012) US

(71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333
Lakeside Drive, Foster City, CA 94404 (US).

(72) Inventors: CULLEN, Aaron, J.; 5050 Hacienda Drive
#314, Dublin, CA 94568 (US). YU, Richard, Hung Chiu;
2625 35th Avenue, San Francisco, CA 94116 (US).

(74) Agents: BOSS, Brandon et al.; Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, CA 94404 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,


AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS



I

(57) Abstract: Methods and intermediates useful for preparing a compound of formula I and salts thereof.


METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS

Cross-Reference to Related Applications



This application claims the benefit of priority from U.S. Provisional Patent Application No. 61/594,686 filed February 3, 2012, the content of which is hereby incorporated by reference herein in its entirety.

Background


International Patent Application Publication Number WO 2008/010921 and International Patent Application Publication Number WO 2008/103949 disclose certain compounds that are reported to be useful to modify the pharmacokinetics of a co-administered drug, e.g. by inhibiting cytochrome P450 monooxygenase. One specific compound identified therein is a compound of formula I.



International Patent Application Publication Number WO 2010/115000 discloses methods for preparing the compound of formula I and salts thereof. Two intermediates discussed in these applications include the compound of formula II and the compound of formula III and salts thereof.




European Patent Application EP 486948 discloses a compound of formula IV' and International Patent Application Publication Number WO 1994/14436 discloses a compound of formula V'.



There is currently a need for improved synthetic methods and intermediates that can be used to prepare the compound of formula I and salts thereof. There is also a need for improved methods and intermediates that can be used to prepare the compound of formula II and the compound of formula III which are useful for preparing the compound of formula I. The improved methods and intermediates may reduce the cost, time, and/or the amount of waste or provide an increased yield associated with the existing methods for preparing the compounds of formula I or formula II or formula III or salts or protected derivatives thereof.

Summary

A new synthetic processes and intermediates would be useful for preparing the compound of formula I. In particular, the new synthetic processes and intermediates are useful for preparing intermediates (e.g. the compounds of formula II and III) used to prepare the compound of formula I. Accordingly, in one embodiment a compound is selected from:



wherein:

R^{1a} and R^{1b} are each independently an amine protecting group; or R^{1a} is an amine protecting group and R^{1b} is H;


R^{1c} is $-C(O)O(C_1-C_6)$ alkyl wherein $-C(O)O(C_1-C_6)$ alkyl is optionally substituted with one or more (e.g. 1, 2, 3, 4 or 5) halogen or (C_1-C_6) alkoxy;

R^2 is $-SMe$ or imidazol-1-yl; and


R^4 is $-SO_2(C_1-C_6)$ alkyl or $-SO_2$ aryl, wherein $-SO_2(C_1-C_6)$ alkyl is optionally substituted with one or more (e.g. 1, 2, 3, 4 or 5) halogen, and wherein $-SO_2$ aryl is optionally substituted with one or more (e.g. 1, 2, 3, 4 or 5) halogen, (C_1-C_6) alkyl or NO_2 ;

and salts thereof;


provided the compound is not:



In another embodiment there is a method for preparing a compound of formula 1a or a salt thereof, comprising protecting a compound of formula IVa:




or a salt thereof to provide the corresponding compound of formula 1a:




or the salt thereof, wherein R^{1a} and R^{1b} are each independently an amine protecting group; or R^{1a} is an amine protecting group and R^{1b} is H; and R^{1c} is $-C(O)O(C_1-C_6)alkyl$ wherein $-C(O)O(C_1-C_6)alkyl$ is optionally substituted with one or more halogen or $(C_1-C_6)alkoxy$.

In another embodiment there is a method for preparing a compound of formula 2a or a salt thereof, comprising activating a compound of formula 1a:




or a salt thereof, to provide the corresponding compound of formula 2a:




or the salt thereof, wherein R^{1a} and R^{1b} are each independently an amine protecting group; or R^{1a} is an amine protecting group and R^{1b} is H; R^{1c} is $-C(O)O(C_1-C_6)alkyl$ wherein $-C(O)O(C_1-C_6)alkyl$ is optionally substituted with one or more halogen or $(C_1-C_6)alkoxy$ and R^2 is SMe.

In another embodiment there is a method for preparing a compound of formula 4 or a salt thereof, comprising deoxygenating a compound of formula 2a:




or a salt thereof, to provide the corresponding compound of formula 4:




or the salt thereof, wherein R^{1a} and R^{1b} are each independently an amine protecting group; or R^{1a} is an amine protecting group and R^{1b} is H, R^{1c} is $-C(O)O(C_1-C_6)$ alkyl wherein $-C(O)O(C_1-C_6)$ alkyl is optionally substituted with one or more halogen or (C_1-C_6) alkoxy and R^2 is SMe.

In another embodiment there is a method for preparing a compound of formula 3a or a salt thereof, comprising activating a compound of formula 1a:




or a salt thereof, to provide the corresponding compound of formula 3a:




or the salt thereof, wherein R^{1a} and R^{1b} are each independently an amine protecting group; or R^{1a} is a protecting group and R^{1b} is H; R^{1c} is $-C(O)O(C_1-C_6)$ alkyl wherein $-C(O)O(C_1-C_6)$ alkyl is optionally substituted with one or more halogen or (C_1-C_6) alkoxy; and R^2 is imidazol-1-yl.

In another embodiment there is a method for preparing a compound of formula 4 or a salt thereof, comprising deoxygenating a compound of formula 3a:




or a salt thereof, to provide the corresponding compound of formula 4:




or the salt thereof, wherein R^{1a} and R^{1b} are each independently an amine protecting group; or R^{1a} is an amine protecting group and R^{1b} is H; R^{1c} is $-C(O)O(C_1-C_6)$ alkyl wherein $-C(O)O(C_1-C_6)$ alkyl is optionally substituted with one or more halogen or (C_1-C_6) alkoxy; and R^2 is imidazol-1-yl.

In another embodiment there is a method for preparing a compound of formula 2a' or a salt thereof, comprising activating a compound of formula 1a:




or a salt thereof, to provide the corresponding compound of formula 2a:




or the salt thereof, wherein R^{1a} and R^{1b} are each independently an amine protecting group; or R^{1a} is an amine protecting group and R^{1b} is H; R^{1c} is $-C(O)O(C_1-C_6)$ alkyl wherein $-C(O)O(C_1-C_6)$ alkyl is optionally substituted with one or more halogen or (C_1-C_6) alkoxy and R^2 is SMe or imidazol-1-yl.

In another embodiment there is a method for preparing a compound of formula 4 or a salt thereof, comprising deoxygenating a compound of formula 2a':




or a salt thereof, to provide the corresponding compound of formula 4:




or the salt thereof, wherein R^{1a} and R^{1b} are each independently an amine protecting group; or R^{1a} is an amine protecting group and R^{1b} is H; R^{1c} is -C(O)O(C₁-C₆)alkyl wherein -C(O)O(C₁-C₆)alkyl is optionally substituted with one or more halogen or (C₁-C₆)alkoxy; and R² is SMe or imidazol-1-yl.

In another embodiment there is a method for preparing a compound of formula II or a salt thereof, comprising deprotecting a compound of formula 4:




or a salt thereof, to provide the compound of formula II:




or the salt thereof, wherein R^{1a} and R^{1b} are each independently an amine protecting group; or R^{1a} is an amine protecting group and R^{1b} is H; and R^{1c} is -C(O)O(C₁-C₆)alkyl wherein -C(O)O(C₁-C₆)alkyl is optionally substituted with one or more halogen or (C₁-C₆)alkoxy; provided that R^{1a} is not -C(=O)O(CH₃)₃ when R^{1c} is -C(=O)O(CH₃)₃ and R^{1b} is H.

In another embodiment there is a method for preparing a compound of formula 5 or a salt thereof, comprising deprotecting a compound of formula 4:




or a salt thereof, to provide the corresponding compound of formula 5




or the salt thereof, wherein R^{1a} and R^{1b} are each independently an amine protecting group, or R^{1a} is an amine protecting group and R^{1b} is H; and R^{1c} is -C(O)O(C₁-C₆)alkyl wherein -C(O)O(C₁-C₆)alkyl is optionally substituted with one or more halogen or (C₁-C₆)alkoxy.

In another embodiment there is a method for preparing a compound of formula II or a salt thereof, comprising deprotecting a compound of formula 5:




or a salt thereof, to provide the compound of formula II:




or the salt thereof, wherein R^{1c} is -C(O)O(C₁-C₆)alkyl wherein -C(O)O(C₁-C₆)alkyl is optionally substituted with one or more halogen or (C₁-C₆)alkoxy.

In another embodiment there is a method for preparing a compound of formula 6 or a salt thereof comprising acylating a compound of formula 5:




or a salt thereof, to provide the corresponding compound of formula 6




or the salt thereof, wherein R^{1c} is $-C(O)O(C_1-C_6)$ alkyl wherein $-C(O)O(C_1-C_6)$ alkyl is optionally substituted with one or more halogen or (C_1-C_6) alkoxy.

In another embodiment there is a method for preparing a compound of formula 7a or a salt thereof, comprising activating a compound of formula Va:




or a salt thereof, to provide the corresponding compound of formula 7a:




or the salt thereof, wherein R^{1c} is $-C(O)O(C_1-C_6)$ alkyl wherein $-C(O)O(C_1-C_6)$ alkyl is optionally substituted with one or more halogen or (C_1-C_6) alkoxy.

In another embodiment there is a method for preparing a compound of formula 6 or a salt thereof, comprising deoxygenating a compound of formula 7a:




or a salt thereof, to provide the corresponding compound of formula 6:




or the salt thereof, wherein R^{1c} is $-C(O)O(C_1-C_6)alkyl$ wherein $-C(O)O(C_1-C_6)alkyl$ is optionally substituted with one or more halogen or $(C_1-C_6)alkoxy$.

In another embodiment there is a method for preparing a compound of formula III or a salt thereof, comprising deprotecting a compound of formula 6:




or a salt thereof, to provide the compound of formula III:




or the salt thereof, wherein R^{1c} is $-C(O)O(C_1-C_6)alkyl$ wherein $-C(O)O(C_1-C_6)alkyl$ is optionally substituted with one or more halogen or $(C_1-C_6)alkoxy$.

In another embodiment there is a method for preparing a compound of formula 9a, comprising activating a compound of formula 8a:




or a salt thereof, to provide the corresponding compound of formula 9a:




wherein R^{1a} is $-C(O)OCH_2Ph$, wherein $-C(O)OCH_2Ph$ is optionally substituted with one or more (C_1-C_6) alkyl or (C_1-C_6) alkoxy; R^{1c} is $-C(O)O(C_1-C_6)$ alkyl wherein $-C(O)O(C_1-C_6)$ alkyl is optionally substituted with one or more halogen or (C_1-C_6) alkoxy; and R^4 is $-SO_2(C_1-C_6)$ alkyl or $-SO_2$ aryl, wherein $-SO_2(C_1-C_6)$ alkyl is optionally substituted with one or more halogen, and wherein $-SO_2$ aryl is optionally substituted with one or more halogen, (C_1-C_6) alkyl or NO_2 .

In another embodiment there is a method for preparing a compound of formula 10a or a salt thereof, comprising deprotecting a compound of formula 9a:




to provide the corresponding compound of formula 10a:




or the salt thereof, wherein R^{1a} is $-C(O)OCH_2Ph$, wherein $-C(O)OCH_2Ph$ is optionally substituted with one or more (C_1-C_6) alkyl or (C_1-C_6) alkoxy; R^{1c} is $-C(O)O(C_1-C_6)$ alkyl wherein $-C(O)O(C_1-C_6)$ alkyl is optionally substituted with one or more halogen or (C_1-C_6) alkoxy; and R^4 is $-SO_2(C_1-C_6)$ alkyl or $-SO_2$ aryl, wherein $-SO_2(C_1-C_6)$ alkyl is optionally substituted with one or more halogen, and wherein $-SO_2$ aryl is optionally substituted with one or more halogen, (C_1-C_6) alkyl or NO_2 .

In another embodiment there is a method for preparing a compound of formula 11a or a salt thereof, comprising cyclizing a compound of formula 10a:




or a salt thereof, to provide the corresponding compound of formula 11a:




or the salt thereof, wherein R^{1a} is -C(O)OCH₂Ph, wherein -C(O)OCH₂Ph is optionally substituted with one or more (C₁-C₆)alkyl or (C₁-C₆)alkoxy; and R⁴ is -SO₂(C₁-C₆)alkyl or -SO₂aryl, wherein -SO₂(C₁-C₆)alkyl is optionally substituted with one or more halogen, and wherein -SO₂aryl is optionally substituted with one or more halogen, (C₁-C₆)alkyl or NO₂.

In another embodiment there is a method for preparing a compound of formula II or a salt thereof, comprising ring-opening a compound of formula 11a:




or a salt thereof, to provide the compound of formula II:




or the salt thereof, wherein R^{1a} is -C(O)OCH₂Ph, wherein -C(O)OCH₂Ph is optionally substituted with one or more (C₁-C₆)alkyl or (C₁-C₆)alkoxy.

In another embodiment there is a method for preparing a compound of formula I:




or a salt thereof, comprising converting a compound of formula IVa:




or a salt thereof, into the compound of formula I or the salt thereof, wherein R^{1c} is $-C(O)O(C_1-C_6)$ alkyl wherein $-C(O)O(C_1-C_6)$ alkyl is optionally substituted with one or more halogen or (C_1-C_6) alkoxy,

In another embodiment there is a method for preparing a compound of formula I:




or a salt thereof, comprising converting a compound of formula 1a:




or a salt thereof, into the compound of formula I or the salt thereof, wherein R^{1a} and R^{1b} are each independently an amine protecting group, or R^{1a} is an amine protecting group and R^{1b} is H; and R^{1c} is $-C(O)O(C_1-C_6)$ alkyl wherein $-C(O)O(C_1-C_6)$ alkyl is optionally substituted with one or more halogen or (C_1-C_6) alkoxy.

In another embodiment there is a method for preparing a compound of formula I:




or a salt thereof, comprising converting a compound of formula 2a:




or a salt thereof, into the compound of formula I or the salt thereof, wherein R^{1a} and R^{1b} are each independently an amine protecting group, or R^{1a} is an amine protecting group and R^{1b} is H; R^{1c} is -C(O)O(C₁-C₆)alkyl wherein -C(O)O(C₁-C₆)alkyl is optionally substituted with one or more halogen or (C₁-C₆)alkoxy; and R² is -SMe.

In another embodiment there is a method for preparing a compound of formula I:




or a salt thereof, comprising converting a compound of formula 3a:




or a salt thereof, into the compound of formula I or the salt thereof, wherein R^{1a} and R^{1b} are each independently an amine protecting group, or R^{1a} is an amine protecting group and R^{1b} is H; R^{1c} is -C(O)O(C₁-C₆)alkyl wherein -C(O)O(C₁-C₆)alkyl is optionally substituted with one or more halogen or (C₁-C₆)alkoxy; and R² is imidazol-1-yl.

In another embodiment there is a method for preparing a compound of formula I:




or a salt thereof, comprising converting a compound of formula 4:




or a salt thereof, into the compound of formula I or the salt thereof, wherein R^{1a} and R^{1b} are each independently an amine protecting group, or R^{1a} is an amine protecting group and R^{1b} is H; and R^{1c} is $-C(O)O(C_1-C_6)$ alkyl wherein $-C(O)O(C_1-C_6)$ alkyl is optionally substituted with one or more halogen or (C_1-C_6) alkoxy; provided that R^{1a} is not $-C(=O)O(CH_3)_3$ when R^{1c} is $-C(=O)O(CH_3)_3$ and R^{1b} is H.

In another embodiment there is a method for preparing a compound of formula I:




or a salt thereof, comprising converting a compound of formula 5:




or a salt thereof, into the compound of formula I or the salt thereof, wherein R^{1c} is $-C(O)O(C_1-C_6)$ alkyl wherein $-C(O)O(C_1-C_6)$ alkyl is optionally substituted with one or more halogen or (C_1-C_6) alkoxy.

In another embodiment there is a method for preparing a compound of formula I:




or a salt thereof, comprising converting a compound of formula 6:




or a salt thereof, into the compound of formula I or the salt thereof, wherein R^{1c} is -C(O)O(C₁-C₆)alkyl wherein -C(O)O(C₁-C₆)alkyl is optionally substituted with one or more halogen or (C₁-C₆)alkoxy.

In another embodiment there is a method for preparing a compound of formula I:




or a salt thereof, comprising converting a compound of formula 7a:




or a salt thereof, into the compound of formula I or the salt thereof, wherein R^{1c} is $-C(O)O(C_1-C_6)alkyl$ wherein $-C(O)O(C_1-C_6)alkyl$ is optionally substituted with one or more halogen or $(C_1-C_6)alkoxy$.

In another embodiment there is a method for preparing a compound of formula I:




or a salt thereof, comprising converting a compound of formula 9a:




or a salt thereof, into the compound of formula I or the salt thereof, wherein R^{1a} is $-C(O)OCH_2Ph$, wherein $-C(O)OCH_2Ph$ is optionally substituted with one or more $(C_1-C_6)alkyl$ or $(C_1-C_6)alkoxy$; R^{1c} is $-C(O)O(C_1-C_6)alkyl$ wherein $-C(O)O(C_1-C_6)alkyl$ is optionally substituted with halogen or $(C_1-C_6)alkoxy$; and R^4 is $-SO_2(C_1-C_6)alkyl$ or $-SO_2aryl$, wherein $-SO_2(C_1-C_6)alkyl$ is optionally substituted with one or more halogen, and wherein $-SO_2aryl$ is optionally substituted with one or more halogen, $(C_1-C_2)alkyl$ or NO_2 .

In another embodiment there is a method for preparing a compound of formula I:




or a salt thereof, comprising converting a compound of formula 10a:




or a salt thereof, into the compound of formula I or the salt thereof, wherein R^{1a} is $-C(O)OCH_2Ph$, wherein $-C(O)OCH_2Ph$ is optionally substituted with one or more (C_1-C_6) alkyl or (C_1-C_6) alkoxy; and R^4 is $-SO_2(C_1-C_6)$ alkyl or $-SO_2$ aryl, wherein $-SO_2(C_1-C_6)$ alkyl is optionally substituted with one or more halogen, and wherein $-SO_2$ aryl is optionally substituted with one or more halogen, (C_1-C_6) alkyl or NO_2 .

In another embodiment there is a method for preparing a compound of formula I:




or a salt thereof, comprising converting a compound of formula 11a:




or a salt thereof, into the compound of formula I or the salt thereof, wherein R^{1a} is $-C(O)OCH_2Ph$, wherein $-C(O)OCH_2Ph$ is optionally substituted with one or more (C_1-C_6) alkyl or (C_1-C_6) alkoxy.

In another embodiment there is a method for preparing a compound of formula I:



or a salt thereof, comprising converting a compound of formula Va:



or a salt thereof, into the compound of formula I or the salt thereof, wherein R^{1c} is -C(O)O(C₁-C₆)alkyl wherein -C(O)O(C₁-C₆)alkyl is optionally substituted with one or more halogen or (C₁-C₆)alkoxy.

Detailed Description

The following definitions are used, unless otherwise described:

The term “halo” or “halogen” or “halide” refers to fluoro, chloro, bromo, or iodo.

The terms “alkyl” and “alkoxy” denote both straight and branched groups, but reference to an individual radical such as propyl embraces the straight chain radical, a branched chain isomer such as isopropyl being specifically referred to. The term “(C₁-C₆)alkyl” refers to an alkyl of 1-6 carbon atoms. The term “(C₁-C₆)alkoxy” refers to a (C₁-C₆)alkyl-O- group.

The term “aryl” as used herein refers to a ring structure of from 6 to 14 carbon atoms in the ring. Aryl includes a single aromatic ring (e.g. phenyl). Aryl also includes multiple condensed rings (e.g. bicyclic or multicyclic rings such as naphthyl or anthryl) wherein the condensed rings may be aromatic, saturated or partially saturated, provided that at least one of the condensed rings is aromatic. Such multiple condensed rings may be optionally substituted with one or more (e.g. 1, 2 or 3) oxo groups on any non-aromatic portion (i.e. saturated or partially unsaturated) of the multiple condensed ring. It is to be understood that the point(s) of attachment of a bicyclic or multicyclic aryl can be at any position of the ring system including an aromatic or non-aromatic portion of the ring. Exemplary aryls include, but are not limited to phenyl, indanyl, naphthyl, 1,2-dihydronaphthyl and 1,2,3,4-tetrahydronaphthyl.

The term “leaving group” includes any group that can be displaced by a nucleophile (e.g. an amine or substituted amine, for example, to form a nitrogen-carbon bond). In one embodiment the leaving group is OR⁴. In another embodiment the leaving group is -OS(O)₂R^L, wherein R^L is (C₁-C₆)alkyl or aryl, wherein (C₁-C₆)alkyl is optionally substituted with one or more halogen, and

wherein aryl is optionally substituted with one or more halogen, (C₁-C₆)alkyl or NO₂.

The term "Boc" is -C(=O)OC(CH₃)₃.

A protecting group (PG) is a group of atoms introduced into a molecule to prevent it from undergoing undesired chemical reactions. Chemical protecting groups and strategies for protection/deprotection are well known in the art. *See e.g., Protective Groups in Organic Chemistry*, Theodora W. Greene, John Wiley & Sons, Inc., New York, 1991. Protecting groups are often utilized to mask the reactivity of certain functional groups, to assist in the efficiency of desired chemical reactions, *e.g.*, making and breaking chemical bonds in an ordered and planned fashion. An amine protecting group is a protecting group that is particularly well-suited for protecting amine groups. Such amine protecting groups are well-known in the art and are described in *Protective Groups in Organic Chemistry*, Theodora W. Greene, John Wiley & Sons, Inc., New York, 1991. Amine protecting groups include but are not limited to carbamates (*e.g.* (C₁-C₆)alkyl and arylmethyl (*e.g.* benzyl) carbamates each optionally substituted with one or more (C₁-C₆)alkoxy, (C₁-C₆)alkyl and halo groups), trityl groups (*e.g.* C(aryl)₃ or CPh₃ each optionally substituted with one or more (C₁-C₆)alkoxy, (C₁-C₆)alkyl and halo groups), arylalkyl groups (*e.g.* arylmethyl and benzyl groups optionally substituted with one or more (C₁-C₆)alkoxy, (C₁-C₆)alkyl and halo groups) and silyl groups (*e.g.* -SiR₃ groups wherein each R³ is independently (C₁-C₆)alkyl or aryl, each optionally substituted with one or more (C₁-C₆)alkoxy, (C₁-C₆)alkyl and halo groups).

It will be appreciated by those skilled in the art that a compound having a chiral center may exist in and be isolated in optically active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the following description can encompass processes for preparing racemic, diastereomeric, optically-active, polymorphic, tautomeric, or stereoisomeric form, or mixtures thereof, of a compound described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase).

It is also to be understood that compounds depicted herein may or may not be shown with absolute stereochemistry. If a compound is drawn with stereochemical bonds it is meant to be the specific stereoisomer shown (*e.g.* diastereomer or enantiomer). Accordingly, wherein applicable, in one embodiment the stereoisomer of a compound depicted herein is about >99% enriched in that stereoisomer. In another embodiment the stereoisomer of a compound depicted herein is

about >98% enriched in that stereoisomer. In another embodiment the stereoisomer of a compound depicted herein is about >95% enriched in that stereoisomer. In another embodiment the stereoisomer of a compound depicted herein is about >90% enriched in that stereoisomer. In another embodiment the stereoisomer of a compound depicted herein is about >80% enriched in that stereoisomer. In another embodiment the stereoisomer of a compound depicted herein is about >70% enriched in that stereoisomer. In another embodiment the stereoisomer of a compound depicted herein is about >60% enriched in that stereoisomer. In another embodiment the stereoisomer of a compound depicted herein is about >50% enriched in that stereoisomer.

Specific values listed below for radicals, substituents, and ranges, are for illustration only; they do not exclude other defined values or other values within defined ranges for the radicals and substituents.

Specifically, (C₁-C₆)alkyl can be methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, pentyl, 3-pentyl or hexyl; (C₁-C₆)alkoxy can be methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, sec-butoxy, pentoxy or hexyloxy, heptyloxy.

A specific group of compounds includes compounds wherein R^{1a} and R^{1b} are each independently -C(O)O-CH₂Ph, -C(O)O(C₁-C₆)alkyl or Ph-CH₂-; or R^{1a} is -C(O)O-CH₂Ph, -C(O)O(C₁-C₆)alkyl or Ph-CH₂- and R^{1b} is H; wherein any C(O)O-CH₂Ph, -C(O)O(C₁-C₆)alkyl or Ph-CH₂- of R^{1a} and R^{1b} is optionally substituted with one or more (C₁-C₆)alkyl or (C₁-C₆)alkoxy.

Another specific group of compounds includes wherein R^{1a} is -C(O)O-CH₂Ph and R^{1b} is H, wherein -C(O)O-CH₂Ph is optionally substituted with one or more (C₁-C₆)alkyl or (C₁-C₆)alkoxy.

Another specific group of compounds includes wherein R^{1a} is -C(O)O-CH₂Ph and R^{1b} is H.

A specific value for R^{1a} is -C(O)O-CH₂Ph wherein -C(O)O-CH₂Ph is optionally substituted with one or more (C₁-C₆)alkyl or (C₁-C₆)alkoxy.


Another specific value for R^{1a} is -C(O)O-CH₂Ph.

A specific value for R^{1b} is H.

A specific value for R^{1c} is -C(O)OC(CH₃)₃.

A specific value for R⁴ is p-tolunesulfonyl.

In one embodiment there is a compound which is:



wherein:

R^{1a} and R^{1b} are each independently an amine protecting group; or R^{1a} is an amine protecting group and R^{1b} is H;


R^{1c} is -C(O)O(C₁-C₆)alkyl wherein -C(O)O(C₁-C₆)alkyl is optionally substituted with halogen or (C₁-C₆)alkoxy

R² is SMe or imidazol-1-yl; and


R⁴ is -SO₂(C₁-C₆)alkyl or -SO₂aryl, wherein -SO₂(C₁-C₆)alkyl is optionally substituted with one or more halogen, and wherein -SO₂aryl is optionally substituted with one or more halogen, (C₁-C₆)alkyl or NO₂;

or a salt thereof;

provided the compound is not:




In another embodiment there is a compound which is:



or a salt thereof.

In another embodiment there is a compound which is:




or a salt thereof.


A compound of formula IV or IVa can be converted to a compound of formula III by the method outlined in Scheme 1. The conversion of the compound of formula IV to the compound of formula III includes the activation of the hydroxy group of the compound of formula 1 to provide a corresponding compound of formula 2 or 3, which can then be deoxygenated to provide the corresponding compound of formula 4. As the conversion of the compound of IV to 4 results in the loss of stereochemistry at the hydroxy position, the synthesis of the compound of formula 4 can also utilize the compound of formula IVa (mixture of epimers at the hydroxy position) as the starting material. In a similar manner the compound related to the compound of formula IV wherein the stereochemistry at the hydroxy position is "R" instead of "S" can also serve as a starting material to prepare the compound of formula 4. The compound of formula 4 can be

converted to the compound of formula II or the compound of formula III either of which can be converted to the compound of formula I by the methods described in International Patent Applications WO 2008/010921, WO 2008/103949 and WO 2010/115000 and discussed herein below.

Scheme 1



Preparation of a compound of formula I or 1a:



In one embodiment there is a method of protecting a compound of formula IV (or IVa) or a salt thereof to provide a corresponding compound of formula 1 (or 1a) or a salt thereof, wherein R^{1a} and R^{1b} are each independently an amine protecting group, or R^{1a} is an amine protecting group and R^{1b} is H; and R^{1c} is $-C(O)O(C_1-C_6)\text{alkyl}$ wherein $-C(O)O(C_1-C_6)\text{alkyl}$ is optionally substituted with one or more halogen or $(C_1-C_6)\text{alkoxy}$.

A specific value for R^{1c} is $-C(O)OC(CH_3)_3$. A specific group of compounds of formula I or Ia are compounds wherein R^{1a} or R^{1b} are each independently $-C(O)O-CH_2Ph$, $-C(O)O(C_1-C_6)\text{alkyl}$ or $Ph-CH_2-$, wherein any $C(O)O-CH_2Ph$, $-C(O)O(C_1-C_6)\text{alkyl}$ or $Ph-CH_2-$ of R^{1a} and R^{1b} is optionally substituted with one or more $(C_1-C_6)\text{alkyl}$ or $(C_1-C_6)\text{alkoxy}$. Another specific group of compounds of formula I or Ia are compounds wherein R^{1a} is $-C(O)O-CH_2Ph$, $-C(O)O(C_1-C_6)\text{alkyl}$ or $Ph-CH_2-$ and R^{1b} is H, wherein any $-C(O)O-CH_2Ph$, $-C(O)O(C_1-C_6)\text{alkyl}$ or $Ph-CH_2-$ of R^{1a} is optionally substituted with one or more $(C_1-C_6)\text{alkyl}$ or $(C_1-C_6)\text{alkoxy}$. Another specific group of compounds of formula I or Ia are compounds wherein R^{1a} is $-C(O)O-CH_2Ph$ and R^{1b} is H, wherein any $-C(O)O-CH_2Ph$, of R^{1a} is optionally substituted with one or more $(C_1-C_6)\text{alkyl}$ or $(C_1-C_6)\text{alkoxy}$. Another specific group of compounds of formula I or Ia are compounds wherein R^{1a} is $-C(O)O-CH_2Ph$ and R^{1b} is H. These specific values are also specific values for the embodiments described herein below for the chemistry of Scheme 1.

The compound of formula IV or IVa, or salts thereof, can be protected by any suitable amine protecting group (or groups) under standard conditions to provide the corresponding compound of formula 1 or 1a, respectively, or salts thereof. The amine can be protected with one group wherein R^{1a} is an amine protecting group and R^{1b} is H or the amine can be protected with two groups wherein R^{1a} and R^{1b} are both amine protecting groups wherein the two groups can be the same or different. A variety of suitable reagents are readily available to protect the amine of


the compound of formula IV or IVa to provide the corresponding compound of formula 1 or 1a. For example, a carbamate group (e.g. a Cbz group) can be introduced by means of a Cbz-halide reagent and a benzyl group can be introduced by a benzyl halide reagent. The reaction can be carried out in a variety of suitable solvents or mixtures thereof. Additional reagents may be suitable for a particular protection step such as the inclusion of a suitable base (e.g. an inorganic base such as a metal hydroxide or a metal carbonate or an organic base such as a trialkylamine). The reaction can conveniently be carried out at a temperature from about 0 °C to 25 °C.

In another embodiment there is a method for the conversion of a compound of formula 1 or a salt thereof or a compound of formula 1a or a salt thereof to a compound of formula I or a salt thereof comprising:

a) converting the compound of formula 1 or the compound of formula 1a or salts thereof, to the compound of formula II or the compound of formula III or salts thereof by the steps outlined in Scheme 1 and described herein below; and

b) converting the compound of formula II or the compound of formula III or salts thereof to the compound of formula I or the salt thereof by any of the steps outlined in Schemes 4-12 and described herein below.

Preparation of a compound of formula 2 or 2a:



In one embodiment there is a method for activating a compound of formula 1 (or 1a) or a salt thereof to provide a corresponding compound of formula 2 (or 2a) or a salt thereof, wherein R^{1a} and R^{1b} are each independently an amine protecting group, or R^{1a} is an amine protecting group

and R^{1b} is H; R^{1c} is $-C(O)O(C_1-C_6)$ alkyl wherein $-C(O)O(C_1-C_6)$ alkyl is optionally substituted with one or more halogen or (C_1-C_6) alkoxy; and R^2 is $-SMe$.


The compound of formula 1 or 1a or salts thereof can be activated to provide the corresponding compound of formula 2 or 2a or salts thereof, wherein R^2 is $-SMe$, by the treatment of the compound of formula 1 or 1a with a base (e.g. a metal hydride such as NaH), carbon disulfide (i.e. CS_2) and a methylating reagent (e.g. a methylhalide or methylsulfonate). Suitable solvents include organic solvents such as polar aprotic solvents (e.g. THF). The reaction can conveniently be carried out at a temperature from about $0^\circ C$ to $25^\circ C$.

In another embodiment there is a method for the conversion of a compound of formula 2 or a salt thereof or a compound of formula 2a or a salt thereof to a compound of formula I or a salt thereof comprising:

a) converting the compound of formula 2 or the compound of formula 2a or salts thereof, to the compound of formula II or the compound of formula III or salts thereof by the steps outlined in Scheme 1 and described herein below; and

b) converting the compound of formula II or the compound of formula III or salts thereof to the compound of formula I or the salt thereof by any of the steps outlined in Schemes 4-12 and described herein below.

Preparation of a compound of formula 3 or 3a:



In one embodiment there is a method for activating a compound of formula 1 (or 1a) or a salt thereof to provide a corresponding compound of formula 3 (or 3a) or a salt thereof, wherein

R^{1a} and R^{1b} are each independently an amine protecting group, or R^{1a} is an amine protecting group and R^{1b} is H; R^{1c} is $-C(O)O(C_1-C_6)$ alkyl wherein $-C(O)O(C_1-C_6)$ alkyl is optionally substituted with one or more halogen or (C_1-C_6) alkoxy; and R^2 is imidazol-1-yl.


The compound of formula 1 or 1a or salts thereof can be activated to provide the compound of formula 3 or 3a or salts thereof, wherein R^2 is imidazol-1-yl, by the treatment of the compound of formula 1 or 1a with thiocarbonyldiimidazole and imidazole. Suitable solvents include organic solvents such as polar aprotic solvents (e.g. THF). The reaction can conveniently be carried out at a temperature from about 0 °C to 25 °C.

In another embodiment there is a method for the conversion of a compound of formula 3 or a salt thereof or a compound of formula 3a or a salt thereof to a compound of formula I or a salt thereof comprising:

a) converting the compound of formula 3 or the compound of formula 3a or salts thereof, to the compound of formula II or the compound of formula III or salts thereof by the steps outlined in Scheme 1 and described herein below; and

b) converting the compound of formula II or the compound of formula III or salts thereof to the compound of formula I or the salt thereof by any of the steps outlined in Schemes 4-12 and described herein below.


Preparation of a compound of formula 4:



In one embodiment there is a method for deoxygenating a compound of formula 2 (or 2a) or a salt thereof to provide a corresponding compound of formula 4 or a salt thereof, wherein R^{1a} and R^{1b} are each independently an amine protecting group, or R^{1a} is an amine protecting group and R^{1b} is H; R^{1c} is $-C(O)O(C_1-C_6)$ alkyl wherein $-C(O)O(C_1-C_6)$ alkyl is optionally substituted with one or more halogen or (C_1-C_6) alkoxy; and R^2 is $-SMe$.

A compound of formula 2 or 2a wherein R^2 is $-SMe$ or a salt thereof, can be deoxygenated to provide a corresponding compound of formula 4 wherein R^2 is $-SMe$, by the treatment of the compound of formula 2 or 2a with a hydrogen bond donor (e.g. 1-ethylpiperidine hypophosphate, diethyl phosphite, tributylboron/water) and a radical initiator (e.g. benzoyl peroxide, air). Suitable solvents include organic solvents such as polar and non-polar aprotic solvents (e.g. dioxane, toluene). The reaction can conveniently be carried out at a temperature from about 95 °C to 105 °C.

The conversion of 2 or 2a to 4 as described above can also result in the formation of the corresponding unsaturated compound of formula 4a, depending on the nature of the protecting groups on the nitrogen and the reagents/conditions used in the deoxygenation step.




The olefin can be separated from the compound of formula 4 and reduced to provide the saturated compound (i.e. the compound of formula 4) by a variety of well-known hydrogenation procedures. During the reduction step one or more protecting groups may also be removed. The reduction of the compound of formula 4a can also be carried out without separating the compound of formula 4a from the compound of formula 4 (i.e. reducing the mixture of the compound of formula 4a and the compound of formula 4 to provide the compound of formula 4 or a compound wherein the olefin has been reduced and one or more protecting groups have been removed).

In another embodiment there is a method for the conversion of a compound of formula 4 or a salt thereof to a compound of formula I or a salt thereof comprising:

a) converting the compound of formula 4 or a salt thereof, to the compound of formula II or the compound of formula III or salts thereof by the steps outlined in Scheme 1 and described herein below; and

b) converting the compound of formula II or the compound of formula III or salts thereof to the compound of formula I or the salt thereof by any of the steps outlined in Schemes 4-12 and described herein below.

Preparation of a compound of formula 4:



In one embodiment there is a method for deoxygenating a compound of formula 3 (or 3a) or a salt thereof to provide a corresponding compound of formula 4 or a salt thereof, wherein R^{1a} and R^{1b} are each independently an amine protecting group, or R^{1a} is an amine protecting group and R^{1b} is H; R^{1c} is -C(O)O(C₁-C₆)alkyl wherein -C(O)O(C₁-C₆)alkyl is optionally substituted with one or more halogen or (C₁-C₆)alkoxy; and R² is imidazol-1-yl.

A compound of formula 3 or 3a wherein R² is imidazol-1-yl, or a salt thereof, can be deoxygenated to provide a corresponding compound of formula 4, by the treatment of the compound of formula 3 or 3a with a suitable radical source and a suitable radical initiator. Suitable radical sources include trialkyltin hydrides (e.g. tri-n-butyltin hydride), trialkylsilanes (e.g. triethyl silane), dialkyl phosphites (e.g. dimethyl phosphite, diethyl phosphite, di-t-butyl phosphite, di-isopropyl phosphite and ethylene glycol phosphite), trialkylborons (e.g. tributylboron) with water, and amine salts of hypophosphorus (e.g. diisopropylethylammonium salt of hypophosphorus acid). Suitable radical initiators include AIBN, benzoyl peroxide and air. The reaction can be conveniently carried out in a variety of organic solvents including polar and non-polar aprotic solvents (e.g. dioxane, n-butyl acetate, di-n-butyl ether, diethyl carbonate,

diethoxy ethane, toluene, methylcyclohexane and heptanes). The reaction can conveniently be carried out at a temperature from about 95 °C to 105 °C.


The conversion of 3 or 3a to 4 as described above can also result in the formation of the corresponding unsaturated compound of formula 4a (as described for the conversion of 2 to 4 above) depending on the nature of the protecting groups on the nitrogen and the reagents/conditions used in the deoxygenation step. The compound 4a or the mixture of the compound of formula 4 and formula 4a can be treated in the same manner as described for the conversion of 2 to 4.

In another embodiment there is a method for the conversion of a compound of formula 4 or a salt thereof to a compound of formula I or a salt thereof comprising:

a) converting the compound of formula 4 or a salt thereof, to the compound of formula II or the compound of formula III or salts thereof by the steps outlined in Scheme 1 and described herein below; and

b) converting the compound of formula II or the compound of formula III or salts thereof to the compound of formula I or the salt thereof by any of the steps outlined in Schemes 4-12 and described herein below.

Preparation of a compound of formula 5:



In one embodiment there is a method for deprotecting a compound of formula 4 or a salt thereof to provide a corresponding compound of formula 5 or a salt thereof, wherein R^{1a} and R^{1b} are each independently an amine protecting group, or R^{1a} is an amine protecting group and R^{1b} is H; and R^{1c} is $-\text{C}(\text{O})\text{O}(\text{C}_1-\text{C}_6)\text{alkyl}$ wherein $-\text{C}(\text{O})\text{O}(\text{C}_1-\text{C}_6)\text{alkyl}$ is optionally substituted with one or more halogen or $(\text{C}_1-\text{C}_6)\text{alkoxy}$.

The compound of formula 4 or a salt thereof can be deprotected to provide the corresponding compound of formula 5 or a salt thereof, by the treatment of the compound of formula 4 with an appropriate deprotection reagent. For example, when R^{1a} is a benzyl carbamate


amine protecting group the deprotection can be carried out under hydrogenation conditions. Suitable catalysts include palladium on carbon. Suitable solvents include organic solvents such as polar protic solvents (e.g. ethanol). The reaction can conveniently be carried out at a temperature from about 0 °C to 60 °C.

In another embodiment there is a method for the conversion of a compound of formula 5 or a salt thereof to a compound of formula I or a salt thereof comprising:

a) converting the compound of formula 5 or the or the salts thereof, to the compound of formula II or the compound of formula III or salts thereof by the steps outlined in Scheme 1 and described herein below; and

b) converting the compound of formula II or the compound of formula III or salts thereof to the compound of formula I or the salt thereof by any of the steps outlined in Schemes 4-12 and described herein below.

Preparation of a compound of formula II:




In one embodiment there is a method for deprotecting a compound of formula 5 or a salt thereof to provide the compound of formula II or a salt thereof, wherein R^{1c} is -C(O)O(C₁-C₆)alkyl wherein -C(O)O(C₁-C₆)alkyl is optionally substituted with one or more halogen or (C₁-C₆)alkoxy.

The compound of formula 5 or a salt thereof can be deprotected to provide the compound of formula II or a salt thereof, by the treatment of the compound of formula 5 with an appropriate deprotection reagent. For example, when R^{1c} is -OC(=O)O(CH₃)₃ the deprotection can be carried by treatment of the compound of formula 5 with an acid. Suitable acids include mineral acids (e.g. hydrochloric acid) and organic acids (e.g. TFA). Suitable solvents include organic solvents such as polar protic solvents (e.g. ethanol) and aprotic solvents (e.g. methylene chloride). The reaction can conveniently be carried out at a temperature from about 0 °C to 22 °C.

In another embodiment, (subsequent to the conversion of 5 to II), there is a method for the conversion of a compound of formula II or a salt thereof to a compound of formula I or a salt thereof comprising converting the compound of formula II or the salt thereof to the compound of

formula I or the salt thereof by any of the steps outlined in Schemes 4-12 and described herein below.

Preparation of a compound of formula 6:



In one embodiment there is a method for acylating a compound of formula 5 or a salt thereof to provide a corresponding compound of formula 6 or a salt thereof, wherein R^{1c} is -C(O)O(C₁-C₆)alkyl wherein -C(O)O(C₁-C₆)alkyl is optionally substituted with halogen or (C₁-C₆)alkoxy.

The compound of formula 5 or a salt thereof can be acylated to provide the corresponding compound of formula 6 or a salt thereof, by the treatment of the compound of formula 5 with a compound of formula VIII, or a salt thereof (as described herein below) in the presence of a suitable base in a suitable solvent. Suitable bases include carbonate bases (e.g. potassium carbonate) and trialkylamines (e.g. diisopropylethylamine, or *N*-methyl morpholine). Suitable solvents include solvents such as dichloromethane, tetrahydrofuran, 1,2-dichloroethane, isopropylacetate, and diethylether, and mixtures thereof. The reaction can conveniently be carried out at a temperature from about 0 °C to 22 °C.

In another embodiment there is a method for the conversion of a compound of formula 6 or a salt thereof to a compound of formula I or a salt thereof comprising:


a) deprotecting the compound of formula 6 or the salt thereof, to the compound of formula III or the salt thereof by the steps outlined in Scheme 1 and Scheme 2 and described herein below; and

b) converting the compound of formula III or the salt thereof to the compound of formula I or the salt thereof by any of the steps outlined in Schemes 5-12 and described herein below.


A compound of formula V or Va can be converted to a compound of formula 6 by the method outlined in Scheme 2. The conversion of the compound of formula V to the compound of formula 6 includes the activation of the hydroxy group of the compound of formula V to provide

a compound of formula 7 that can then be deoxygenated to provide the compound of formula 6. As the conversion of the compound of formula V to 6 results in the loss of stereochemistry at the hydroxy position, the synthesis of the compound of formula 6 can also utilize the compound of formula Va (mixture of epimers at the hydroxy position) as the starting material. In a similar manner the compound related to the compound of formula V wherein the stereochemistry at the hydroxy position is "R" instead of "S" can also serve as a starting material to prepare the compound of formula 6. The compound of formula 6 can be converted to the compound of formula III. The compound of formula III can be converted to the compound of formula I by the methods described in International Patent Applications WO 2008/010921, WO 2008/103949 and WO 2010/115000 and discussed herein below.

Scheme 2



Preparation of a compound of formula 7 or 7a:



In one embodiment there is a method for activating a compound of formula V (or Va) or a salt thereof to provide a corresponding compound of formula 7 (or 7a) or a salt thereof, wherein R^{1c} is -C(O)O(C₁-C₆)alkyl wherein -C(O)O(C₁-C₆)alkyl is optionally substituted with one or more halogen or (C₁-C₆)alkoxy.

A specific value for R^{1c} is -C(O)OC(CH₃)₃. This specific value is also a specific value for the embodiments described herein below for the chemistry of Scheme 2.


The compound of formula V or Va or salts thereof can be activated to provide the compound of formula 7 or 7a, or salts thereof, by the treatment of the compound of formula V or Va with thiocarbonyldiimidazole and imidazole. Suitable solvents include organic solvents such as polar aprotic solvents (e.g. THF). The reaction can conveniently be carried out at a temperature from about 0 °C to 25 °C.

In another embodiment there is a method for the conversion of a compound of formula 7 or a salt thereof or a compound of formula 7a or a salt thereof to a compound of formula I or a salt thereof comprising:

a) converting the compound of formula 7 or the compound of formula 7a or the salts thereof, to the compound of formula III or the salt thereof by the steps outlined in Scheme 2 and described herein below; and

b) converting the compound of formula III or the salt thereof to the compound of formula I or the salt thereof by any of the steps outlined in Schemes 5-12 and described herein below.

Preparation of a compound of formula 6:



In one embodiment there is a method for deoxygenating a compound of formula 7 (or 7a) or a salt thereof to provide a corresponding compound of formula 6 or a salt thereof, wherein R^{1c} is $-C(O)O(C_1-C_6)$ alkyl wherein $-C(O)O(C_1-C_6)$ alkyl is optionally substituted with one or more halogen or (C_1-C_6) alkoxy.


A compound of formula 7 or 7a, or a salt thereof, can be deoxygenated to provide a corresponding compound of formula 6, by the treatment of the compound of formula 7 or 7a with a suitable radical source and a suitable radical initiator. Suitable radical sources include trialkyltin hydrides (e.g. tri-*n*-butyltin hydride), trialkylsilanes (e.g. triethyl silane), dialkyl phosphites (e.g. dimethyl phosphite, diethyl phosphite, di-*t*-butyl phosphite, di-isopropyl phosphite and ethylene glycol phosphite), trialkylborons (e.g. tributylboron) with water, and amine salts of hypophosphorus e.g. diisopropylethylammonium salt of hypophosphorus acid). Suitable radical initiators include AIBN, benzoyl peroxide and air. Suitable solvents include organic solvents such as polar and non-polar aprotic solvents (e.g. dioxane, *n*-butyl acetate, di-*n*-butyl ether, diethyl carbonate, diethoxy ethane, toluene, methylcyclohexane and heptanes). The reaction can conveniently be carried out at a temperature from about 75 °C to 100 °C.

In another embodiment there is a method for the conversion of a compound of formula 6 or a salt thereof to a compound of formula I or a salt thereof comprising:

a) converting the compound of formula 6 or the salt thereof, to the compound of formula III or the salt thereof by the step outlined in Scheme 2 and described herein below; and

b) converting the compound of formula III or the salt thereof to the compound of formula I or the salt thereof by any of the steps outlined in Schemes 5-12 and described herein below.

Preparation of a compound of formula III:



In one embodiment there is a method for deprotecting a compound of formula 6 or a salt thereof to provide a compound of formula III or a salt thereof, wherein R^{1c} is -C(O)O(C₁-C₆)alkyl wherein -C(O)O(C₁-C₆)alkyl is optionally substituted with halogen or (C₁-C₆)alkoxy.







A compound of formula 6, or a salt thereof, can be deprotected to provide a compound of formula III, by the treatment of the compound of formula 6 with an appropriate reagent to remove the amine protecting group. For example, a compound of formula 6 wherein R^{1c} is -C(O)OC(CH₃)₃ can be deprotected by treatment of 6 with an acid (e.g. trifluoroacetic acid, hydrochloric acid) either in the presence or absence of a suitable solvent. Suitable solvents include organic solvents such as (e.g. dioxane, methylene chloride). The reaction can conveniently be carried out at a temperature from about 0 °C to 22 °C.


In another embodiment, (subsequent to the conversion of 6 to III), there is a method for the conversion of a compound of formula III or a salt thereof to a compound of formula I or a salt thereof comprising converting the compound of formula III or the salt thereof to the compound of formula I or the salt thereof by any of the steps outlined in Schemes 5-12 and described herein below.

A compound of formula IV or IVa can be converted to a compound of formula 6 by the method outlined in Scheme 3. The conversion of the compound of formula IV to the compound of formula 6 includes the conversion of the hydroxy group of the compound of formula IV to a leaving group (e.g. a corresponding compound of formula 9) wherein the leaving group is internally displaced to provide the corresponding aziridine compound of formula 11. The compound of formula 11 can be ring-opened to provide the compound of formula II. As the conversion of compound of IV to II results in the loss of stereochemistry at the hydroxy position, the synthesis of the compound of formula II can also utilize the compound of formula IVa (mixture

of epimers at the hydroxy position) as the starting material. In a similar manner the corresponding compound of formula IV wherein the stereochemistry at the hydroxy position is "R" instead of "S" can also serve as a starting material to prepare the compound of formula 12. The compound of formula II can be converted to the compound of formula I by the methods described in International Patent Applications WO 2008/010921, WO 2008/103949 and WO 2010/115000 and discussed herein below.

Scheme 3



Preparation of a compound of formula 8 or 8a:

In one embodiment there is a method of protecting a compound of formula IV (or IVa) or a salt thereof to provide a corresponding compound of formula 8 (or 8a) or a salt thereof, wherein R^{1a} is -C(O)OCH₂Ph, wherein -C(O)OCH₂Ph is optionally substituted with one or more (C₁-C₆)alkyl or (C₁-C₆)alkoxy; and R^{1c} is -C(O)O(C₁-C₆)alkyl wherein -C(O)O(C₁-C₆)alkyl is optionally substituted with one or more halogen or (C₁-C₆)alkoxy.

A specific value for R^{1c} is -C(O)OC(CH₃)₃. A specific value for R^{1a} is -C(O)O-CH₂Ph. These specific values are also specific values for the embodiments described herein below for the chemistry of Scheme 3.


The compound of formula IV or IVa, or salts thereof, can be protected by any benzyl carbamate protecting group under standard conditions to provide the compound of formula 8 or 8a, or salts thereof. A variety of suitable reagents are available to convert the amine of IV or IVa to the protected amine of compound 8 or 8a. For example, a benzyl carbamate protecting group (e.g. a Cbz group) can be introduced by means of an appropriate haloformate reagent (e.g. benzyl chloroformate). Additional reagents may be required for a particular protection step such as the inclusion of a suitable base. Suitable bases include organic bases (e.g. amine bases including alkylamines such as diisopropylethylamine, triethylamine, N-methyl morpholine), metal hydrides (e.g. potassium hydride), alkoxides (e.g. sodium *tert*-butoxide), and carbonate bases (e.g. potassium carbonate or cesium carbonate). Suitable solvents include aprotic organic solvents (e.g. pyridine) or mixtures thereof. The reaction can conveniently be carried out at a temperature from about 0 °C to 25 °C.

In another embodiment there is a method for the conversion of a compound of formula 8 or a salt thereof or a compound of formula 8a or a salt thereof to a compound of formula I or a salt thereof comprising:

a) converting the compound of formula 8 or the compound of formula 8a or the salts thereof, to the compound of formula II or the salt thereof by the steps outlined in Scheme 3 and described herein below; and

b) converting the compound of formula II or the salt thereof to the compound of formula I or the salt thereof by any of the steps outlined in Schemes 4-12 and described herein below.

Preparation of a compound of formula 9 or 9a:



In one embodiment there is a method of activating a compound of formula 8 (or 8a) or a salt thereof to provide a corresponding compound of formula 9 (or 9a) wherein R^{1a} is -C(O)OCH₂Ph, wherein -C(O)OCH₂Ph is optionally substituted with one or more (C₁-C₆)alkyl or (C₁-C₆)alkoxy; R^{1c} is -C(O)O(C₁-C₆)alkyl wherein -C(O)O(C₁-C₆)alkyl is optionally substituted with one or more halogen or (C₁-C₆)alkoxy; and R⁴ is -SO₂(C₁-C₆)alkyl or -SO₂aryl, wherein -SO₂(C₁-C₆)alkyl is optionally substituted with one or more halogen, and wherein -SO₂aryl is optionally substituted with one or more halogen, (C₁-C₆)alkyl or NO₂.

A specific value for R⁴ is p-toluenesulfonyl. This specific value is also a specific value for the embodiments described herein below for the chemistry of Scheme 3.



The compound of formula 8 or 8a, or salts thereof, can be converted to the corresponding compound of formula 9 or 9a by a variety of suitable reagents available to convert a hydroxy group to a leaving group. For example, a sulfonate leaving group (e.g. tosylate, mesylate, trifluoromethanesulfonate) can be prepared utilizing a variety of sulfonating reagents such as a sulfonyl halide (e.g. a sulfonyl chloride such as p-toluenesulfonyl chloride) or a sulfonic anhydride and a base including amine bases (e.g. alkylamines such as diisopropylethylamine, triethylamine, N-methyl morpholine), metal hydrides (e.g. potassium hydride), tetramethylpiperidides, alkoxides (e.g. sodium *tert*-butoxide), hexamethyldisilazides and carbonate bases (e.g. potassium carbonate or cesium carbonate). Suitable solvents include organic solvents such as aprotic organic solvents (e.g. pyridine, tetrahydrofuran and 2-methyltetrahydrofuran) or mixtures thereof. The reaction can conveniently be carried out at a temperature from about 0 °C to 25 °C.

In another embodiment there is a method for the conversion of a compound of formula 9 or a salt thereof or a compound of formula 9a or a salt thereof to a compound of formula I or a salt thereof comprising:

a) converting the compound of formula 9 or the compound of formula 9a or the salts thereof, to the compound of formula II or the salt thereof by the steps outlined in Scheme 3 and described herein below; and

b) converting the compound of formula II or the salt thereof to the compound of formula I or the salt thereof by any of the steps outlined in Schemes 4-12 and described herein below.

Preparation of a compound of formula 10 or 10a:



In one embodiment there is a method of deprotecting a compound of formula 9 (or 9a) or a salt thereof to provide a corresponding compound of formula 10 (or 10a) or a salt thereof, wherein R^{1a} is -C(O)OCH₂Ph, wherein -C(O)OCH₂Ph is optionally substituted with one or more (C₁-C₆)alkyl or (C₁-C₆)alkoxy; R^{1c} is -C(O)O(C₁-C₆)alkyl wherein -C(O)O(C₁-C₆)alkyl is optionally substituted with one or more halogen or (C₁-C₆)alkoxy; and R⁴ is -SO₂(C₁-C₆)alkyl or -SO₂aryl, wherein -SO₂(C₁-C₆)alkyl is optionally substituted with one or more halogen, and wherein -SO₂aryl is optionally substituted with one or more halogen, (C₁-C₆)alkyl or NO₂.


The compound of formula 9 or 9a, or salts thereof, can be deprotected under standard conditions to provide the corresponding compound of formula 10 or 10a or salts thereof. For example, the deprotection can be carried out with an acid such as an organic acid (e.g. trifluoroacetic acid) or a mineral acid (e.g. hydrochloric acid). Suitable solvents include organic solvents such as methylene chloride and trifluoroacetic acid or mixtures thereof. The reaction can be conveniently carried out at a temperature from about 0 °C to 25 °C.

In another embodiment there is a method for the conversion of a compound of formula 10 or a salt thereof or a compound of formula 10a or a salt thereof to a compound of formula I or a salt thereof comprising:

a) converting the compound of formula 10 or the compound of formula 10a or the salts thereof, to the compound of formula II or the salt thereof by the steps outlined in Scheme 3 and described herein below; and

b) converting the compound of formula II or the salt thereof to the compound of formula I or the salt thereof by any of the steps outlined in Schemes 4-12 and described herein below.

Preparation of a compound of formula 11 or 11a:



In one embodiment there is a method of cyclizing a compound of formula 10 (or 10a) or a salt thereof to provide a corresponding compound of formula 11 (or 11a) or a salt thereof, wherein R^{1a} is -C(O)OCH₂Ph, wherein -C(O)OCH₂Ph is optionally substituted with one or more (C₁-C₆)alkyl or (C₁-C₆)alkoxy; and R⁴ is -SO₂(C₁-C₆)alkyl or -SO₂aryl, wherein -SO₂(C₁-C₆)alkyl is optionally substituted with one or more halogen, and wherein -SO₂aryl is optionally substituted with one or more halogen, (C₁-C₆)alkyl or NO₂.


The compound of formula 10 or 10a, or salts thereof, can be cyclized to provide the corresponding aziridine of formula 11 or 11a, or salts thereof. The cyclization can be carried out by treatment of the compound of formula 10 or 10a with a base such as a metal hydride (e.g. sodium hydride, potassium hydride, calcium hydride), metal alkoxide (e.g. potassium *tert*-butoxide, sodium, *tert*-butoxide, lithium *tert*-butoxide), alkylamide (e.g. lithium diisopropylamide), hexamethyldisilazides (e.g. lithium hexamethyldisilazide) or carbonate base (e.g. potassium carbonate or cesium carbonate). Suitable solvents include organic solvents such as aprotic organic solvents (e.g. tetrahydrofuran, 2-methyltetrahydrofuran). The reaction can be conveniently carried out at a temperature from about -20 °C to 40 °C.

In another embodiment there is a method for the conversion of a compound of formula 11 or a salt thereof or a compound of formula 11a or a salt thereof to a compound of formula I or a salt thereof comprising:

a) converting the compound of formula 11 or the compound of formula 11a or the salts thereof, to the compound of formula II or the salt thereof by the steps outlined in Scheme 3 and described herein below; and

b) converting the compound of formula II or the salt thereof to the compound of formula I or the salt thereof by any of the steps outlined in Schemes 4-12 and described herein below.

Preparation of a compound of formula II or IIa:




In one embodiment there is a method of ring-opening a compound of formula 11 (or 11a) or a salt thereof to provide a corresponding compound of formula II or a salt thereof, wherein R^{1a} is -C(O)OCH₂Ph, wherein -C(O)OCH₂Ph is optionally substituted with one or more (C₁-C₆)alkyl or (C₁-C₆)alkoxy.

The compound of formula 11 or 11a, or salts thereof, can be ring-opened to provide the compound of formula II, or a salt thereof. The ring-opening of the compound of formula 11 or 11a can be carried out under hydrogenation conditions such as those utilizing a hydrogenation catalyst and hydrogen gas. Suitable hydrogenation catalysts include palladium on carbon (e.g. 10% palladium on carbon), Raney nickel, and Wilkinson's catalyst. Suitable solvents include protic organic solvents such as methanol, ethanol or isopropanol. The reaction can be conveniently carried out at a temperature from about 25 °C to 40 °C.

The compound of formula II can be optionally converted to an amine-protected version of compound II such as a compound of formula 12 or a salt thereof, wherein each R^{1d} is independently an amine protecting group. Suitable amine protecting groups include, for example (C₁-C₆)alkyl alkyl carbamates and arylmethyl carbamates (e.g. t-butyl carbamate, benzyl carbamate) wherein the carbamates can be optionally substituted with one or more or more (C₁-C₆)alkyl or (C₁-C₆)alkoxy groups. Such protection of the diamine may enhance isolation or purification. The protection step can be carried out with a suitable reagent to introduce a protecting group such as a carbamate anhydride (e.g. di-t-butyl dicarbonate) and a suitable base such as amine bases (e.g. alkylamines such as diisopropylethylamine, triethylamine, *N*-methyl morpholine) or an inorganic base such as a carbonate bases (e.g. potassium carbonate or cesium carbonate). Suitable solvents include aprotic organic solvents such as tetrahydrofuran or methylene chloride. The reaction can be conveniently carried out at a temperature from about 0 °C to 25 °C. Such a step can facilitate purification and or isolation. The compound of formula 12 or a salt thereof can be conveniently converted back to the compound of formula II or a salt thereof or the compound of formula 6 or a salt thereof by procedures described herein.

In another embodiment, (subsequent to the conversion of 11 or 11a to II), there is a method for the conversion of a compound of formula II or a salt thereof to a compound of formula I or a salt thereof comprising converting the compound of formula II or the salt thereof to the compound of formula I or the salt thereof by any of the steps outlined in Schemes 4-12 and described herein below.

Alternative preparation of the compound of formula 4:



In one embodiment there is a method of reducing a compound of formula 9 (or 9a) or a salt thereof to provide a corresponding compound of formula 4 or a salt thereof, wherein R^{1a} is $-\text{C}(\text{O})\text{OCH}_2\text{Ph}$, wherein $-\text{C}(\text{O})\text{OCH}_2\text{Ph}$ is optionally substituted with one or more $(\text{C}_1\text{-C}_6)$ alkyl or $(\text{C}_1\text{-C}_6)$ alkoxy; R^{1c} is $-\text{C}(\text{O})\text{O}(\text{C}_1\text{-C}_6)$ alkyl wherein $-\text{C}(\text{O})\text{O}(\text{C}_1\text{-C}_6)$ alkyl is optionally substituted with one or more halogen or $(\text{C}_1\text{-C}_6)$ alkoxy; and R^4 is $-\text{SO}_2(\text{C}_1\text{-C}_6)$ alkyl or $-\text{SO}_2$ aryl, wherein $-\text{SO}_2(\text{C}_1\text{-C}_6)$ alkyl is optionally substituted with one or more halogen, and wherein $-\text{SO}_2$ aryl is optionally substituted with one or more halogen, $(\text{C}_1\text{-C}_6)$ alkyl or NO_2 .

The compound of formula 9 or 9a, or salts thereof, can be reduced to provide the corresponding compound of formula 4, or a salt thereof. The reduction can be carried out by treating 9 or 9a with reducing agent such as a hydride reducing agent. Suitable hydride reducing agents include sodium hydride, potassium hydride, and sodium borohydride. Suitable solvents include ethereal solvents such as tetrahydrofuran, 2-methyltetrahydrofuran, 1,4-dioxane, and ethyl ether. The reaction can be conveniently carried out at a temperature from about $0\text{ }^\circ\text{C}$ to $60\text{ }^\circ\text{C}$.

In another embodiment there is a method for the conversion of a compound of formula 4 or a salt thereof to a compound of formula I or a salt thereof comprising:


a) converting the compound of formula 4 or a salt thereof, to the compound of formula II or the compound of formula III or salts thereof by the steps outlined in Scheme 1 and described herein above; and

b) converting the compound of formula II or the compound of formula III or salts thereof to the compound of formula I or the salt thereof by any of the steps outlined in Schemes 4-12 and described herein below.


Preparation of the compound of formula I:

The compounds of formula II and III can be converted to the compound of formula I following procedures described in International Patent Application WO2010/115000 (pages 26-32). Schemes 4, 5, 6 and 7 outline these procedures.


Scheme 4




Scheme 5



Scheme 6




Preparation of a compound of formula VIII:




The mixed carbonate of formula VIII can be prepared by treating 5-hydroxymethylthiazole with a suitable carbonate or carbonate equivalent having a leaving group adjacent to the carbonyl carbon, such as phosgene in the presence of a base. For example, suitable carbonates include bis-(4-nitrophenyl)carbonate and disuccinimidyl carbonate. The reaction can conveniently be carried out in a suitable aprotic organic solvent, such as dichloromethane, tetrahydrofuran, 1,2-dichloroethane, or diethylether, or a mixture thereof. Suitable bases include trialkylamine bases, such as diisopropylethylamine, *N*-methyl morpholine, and triethylamine.

Preparation of a compound of formula III or a salt thereof




A compound of formula III or a salt thereof can be prepared from a compound of formula II or a salt thereof by treatment with a carbonate of formula VIII or a salt thereof in the presence of a suitable base in a suitable solvent. Suitable bases include carbonate bases (e.g. potassium carbonate) and trialkylamines (e.g. diisopropylethylamine, or *N*-methyl morpholine). Suitable solvents include solvents such as dichloromethane, tetrahydrofuran, 1,2-dichloroethane, isopropylacetate, and diethylether, and mixtures thereof.

Preparation of a compound of formula XI:



A compound of formula XI wherein R_3 is H or a salt thereof can be prepared by treating L-methionine with an alkylating agent in the presence of water and acetic acid. Suitable alkylating agents include alkyl bromides (bromoacetic acid), alkyl iodides, alkyl chlorides, and dimethyl sulfate. The reaction can conveniently be carried out in a solvent that comprises an alcohol (e.g. isopropanol), water, and acetic acid. The reaction can be carried out at a temperature from about 22 °C to about 90 °C. A compound of formula XI wherein R_3 is a protecting group (e.g. a carbamate, amide, or benzyl protecting group) or a salt thereof can be prepared by protecting a corresponding compound of formula XI wherein R_3 is hydrogen to provide the compound of formula XI wherein R_3 is a protecting group or the salt thereof.


Preparation of a compound of formula XII:



A compound of formula XII can be prepared by treating a compound of formula XI wherein R_3 is H or a protecting group (e.g. a carbamate, amide, or benzyl protecting group), or a salt thereof with a compound of formula XIX or a salt thereof, in an aprotic solvent at a temperature from about 0 °C to about 30 °C in the presence of a suitable base and a carbonyl source, such as CDI. When R_3 is a protecting group it can subsequently be removed to provide the compound of formula XII or the salt thereof. Suitable bases include metal hydrides (e.g. sodium hydride), and trialkylamines (e.g. diisopropylethylamine, triethylamine, *N*-methyl morpholine or


DBU). Suitable aprotic solvents include tetrahydrofuran, 2-methyltetrahydrofuran, and dichloromethane, and mixtures thereof.

Preparation of a compound of formula XIII:



A compound of formula XIII can be prepared by treating a compound of formula XII or a salt thereof with a suitable iodide source (e.g. trimethylsilyl iodide, hydrogen iodide, or sodium iodide and trimethylsilyl chloride) in an aprotic solvent in the presence of an alcohol ROH to provide the compound of formula XIII wherein R is (C₁-C₈)alkyl. Suitable aprotic solvents include tetrahydrofuran, 2-methyltetrahydrofuran, dichloromethane, and acetonitrile, and mixtures thereof. The reaction can typically be carried out at a temperature from about 0 °C to about 22 °C.


Preparation of a compound of formula XIV or a salt thereof:



A compound of formula XIV or a salt thereof can be prepared by treating a compound of formula XIII wherein R is (C₁-C₈)alkyl with morpholine to provide the compound of formula XIV or the salt thereof. The resulting compound of formula XIV can be converted to a corresponding salt by treatment with an acid (e.g. an organic acid such as oxalic acid, citric acid, or fumaric acid, or a mineral acid) in an organic solvent. Suitable solvents include *tert*-butyl methyl ether,


methylene chloride, tetrahydrofuran, acetone, acetonitrile, toluene, heptanes, isopropyl acetate, ethyl acetate and alcohols, and mixtures thereof. The salt formation can typically be carried out at a temperature from about 22 °C to about 60 °C.

Preparation of a compound of formula X:



A compound of formula X wherein M^+ is a counterion, or a salt thereof, can be prepared by hydrolyzing an ester of formula XIV wherein R is (C₁-C₈)alkyl or a salt thereof under standard conditions. For example, the hydrolysis can be carried out in an aqueous solvent (e.g. water and dichloromethane) in the presence of a base (e.g. potassium hydroxide or lithium hydroxide) at a temperature from about -10 °C to about 28 °C.

Preparation of a compound of formula I:




A compound of formula I or a salt thereof can be prepared by coupling an acid salt of formula X wherein M^+ is a counterion with an amine of formula III to form the corresponding amide. This amide forming reaction can be carried out under standard conditions. For example, it can be carried out in a suitable organic solvent (e.g. dichloromethane) in the presence of a

suitable coupling agent (e.g. EDC•HCl and HOBt). Other suitable amide coupling reagents and conditions are known in the field. The reaction can typically be carried out at a temperature from about -30 °C to about 20 °C.

The resulting compound of formula I can be isolated using standard techniques. The compound of formula I as described here or throughout the application can be isolated employing a solid support material as described in International Patent Application Publication Number WO 2009/135179

Alternative preparation of the compound of formula I:




A compound of formula I or a salt thereof can be prepared by coupling an acid of formula Xa or a salt thereof with an amine of formula III or a salt thereof to form the corresponding amide. This amide forming reaction can be carried out under standard conditions. For example, it can be carried out in a suitable organic solvent (e.g. dichloromethane) in the presence of a suitable coupling agent (e.g. EDC•HCl and HOBt). Other suitable amide coupling reagents and conditions are known in the field. The reaction can typically be carried out at a temperature from about -30 °C to about 20 °C.

Alternative preparation of a compound of formula XII:

The compound of formula XII shown in Scheme 5 above can also be prepared as illustrated in Scheme 7.

Scheme 7



Preparation of a compound of formula XII


The amine of formula XV or a salt thereof can be treated with carbonyldiimidazole, in the presence of a suitable base (e.g. a trialkylamine, such as triethylamine, *N*-methyl morpholine, diisopropylethylamine, or DBU; a hydride base, such as sodium hydride; or an amide base, such as LiHMDS) in an aprotic solvent (e.g. tetrahydrofuran, or 2-methyltetrahydrofuran) to provide the urea of formula XVI. Alkylation of the urea of formula XVI with a suitable methylating agent (e.g. methyl iodide) in the presence of a base in an aprotic solvent provides a compound of formula XVII. Further alkylation with a suitable methylating agent (e.g. methyl iodide) provides a salt of formula XVIII. Treatment of the salt of formula XVIII with an *N*-unprotected amino γ -lactone of formula XI or with a corresponding *N*-protected amino γ -lactone (e.g. a carbamate, amide or benzylamine) in a suitable aprotic solvent (e.g. tetrahydrofuran, or 2-methyltetrahydrofuran) in the presence of a suitable base (e.g. a trialkylamine, such as triethylamine, *N*-methyl morpholine, diisopropylethylamine, or DBU) provides the compound of formula XII. If an *N*-protected amino γ -lactone is utilized in the previously described step (i.e. Compound XI where R₃ is a protecting group), the resulting protected product can be deprotected to provide the compound of formula XII.

Alternative methods for the preparation of the compound of formula I:

The compounds of formula II and III can also be converted to the compound of formula I following procedures described in International Patent Application Publication Number WO 2008/010921 (pages 212-221) and International Patent Application Publication Number WO 2008/103949 (pages 248-259). Methods I-IV (including Schemes 8-12) and the subsequent experimental write-ups depicted below describe these procedures.

Method I:

Scheme 8



i) CDI, DIPEA, CH₂Cl₂; ii) LiOH, THF/H₂O; iii) Cmpd of formula III, DIPEA, EDC, HOBT, THF;
 iv) a. HCl/dioxane; b. Na₂CO₃; v) (BrCH₂CH₂)₂O, NaHCO₃, DMF

Compound 50

Compound 50 is commercially available from Chem Impex International, and was used without further purification.

Compound 51

Compound 50 (7.0 g, 26.0 mmol) was dissolved in CH₂Cl₂ (330 mL) and 1,1-carbonyldiimidazole (4.22 g, 26.0 mmol) was added, followed by i-Pr₂NEt (19 mL, 104 mmol). The solution was stirred at 25 °C for 12 hours. Compound 9 (4.44 g, 26.0 mmol) was dissolved in 20 mL of CH₂Cl₂ and added to the reaction mixture. The solution was stirred at 25 °C for 7 hours. The solvent was removed *in vacuo* and the residue was diluted with ethyl acetate and washed with water and brine. The organic layers were dried (Na₂SO₄), filtered, and evaporated. Purification by Combiflash® (stationary phase: silica gel; eluent: 66-100% EtOAc/Hexane gradient) gave Compound 51 (7.34 g). m/z: 429.0 (M+H)⁺.

Compound 52

Compound 51 (7.34 g, 17.13 mmol) was dissolved in THF (90 mL) and 1M aqueous LiOH (35 mL) was added. The mixture was stirred at 25 °C for 0.5 hour. The reaction was quenched with 1M HCl (51 mL) and the mixture was adjusted to pH 2. The mixture was extracted with ethyl acetate. The organic layers were dried over Na₂SO₄, filtered, and evaporated to provide Compound 52 (7.00 g). The recovered Compound 52 was used in the next step without further purification. m/z: 415.0 (M+H)⁺.

Compound Q


Compound 52 (2.57 g, 6.21 mmol) was dissolved in THF (67 mL). compound of formula III (2.10 g, 5.13 mmol) was added, followed by HOBt (1.04 g, 7.70 mmol), i-Pr₂NEt (3.67 mL, 20.52 mmol), and EDC (1.82 mL, 10.26 mmol). The mixture was stirred at 25 °C for 12 hours. The solvent was removed under reduced pressure. The residue was diluted with ethyl acetate and washed sequentially with saturated aqueous Na₂CO₃, water, and brine. The organic phase was dried over Na₂SO₄, filtered, and evaporated. Purification by flash column chromatography (stationary phase: silica gel; eluent: 5% iPrOH/CH₂Cl₂) gave Compound Q (3.02 g). m/z: 806.2 (M+H)⁺.

Compound R

Compound Q (3.02 g, 3.74 mmol) was suspended in 4.0 N HCl/dioxane solution (30 mL) and stirred at 25 °C for 3 hours. Solvent was removed under reduced pressure and Et₂O was poured into the reaction mixture. The resulting suspension was stirred vigorously for 1.5 hours. The solid was allowed to settle and the ether layer was decanted. Washing of the precipitate with Et₂O was repeated two more times. The product was dried *in vacuo* to afford a white solid (3.18 g, quantitative yield). Saturated aqueous Na₂CO₃ solution was added to above solid (3.18 g) with stirring until solid disappeared. The aqueous solution was extracted with ethyl acetate. The organic phases were dried over Na₂SO₄, filtered, and evaporated to afford Example R as a yellow foam (2.44g, 81%). The recovered Compound R was used without further purification in the next step. m/z: 706.1 (M+H)⁺.

Compound of formula I

Compound R (1.00g, 1.42 mmol) was dissolved in DMF (20 mL) and bromoethyl ether (196 μL, 1.56 mmol) was added dropwise, followed by NaHCO₃ (0.239 g, 2.84 mmol). The reaction mixture was stirred at 25 °C for 2 hours. The solution was heated to 65 °C and stirred for 12 hours. The solvent was removed under reduced pressure. The residue was diluted with EtOAc and washed sequentially with water and brine. The organic phase was dried over Na₂SO₄ filtered, and evaporated. Purification by reverse-phase HPLC (Phenomenex Synergi® Comb-HTS column, eluent: 5-95% CH₃CN/water) gave the compound of formula I (580 mg, 53%). ¹H NMR (CDCl₃) δ 8.98 (s, 1H); 7.90 (s, 1H); 7.75 (m, 1H); 7.40-7.00 (m, 11H), 6.55 (br s, 1H); 5.58 (m, 1H); 5.28, 5.19 (d_{AB}, J=14 Hz, 2H); 4.70-4.37 (m, 3H); 3.99 (m, 5H); 3.76 (br s, 1H); 3.65-3.30 (m, 3H); 2.97 (m, 5H); 2.90-2.60 (m, 6H); 2.28 (br s, 1H); 1.91 (br s, 1H); 1.60-1.30 (m, 10H). m/z: 776.2 (M+H)⁺


Method II:

Compound 54

Compound 54 was prepared following the procedure described in *J. Med. Chem.* 1993, 36, 1384 (herein incorporated by reference in its entirety for all purposes).

To solution of Compound 53 (0.550 g, 5.28 mmol) (Sigma-Aldrich) in H₂O (8.8 mL) at 0 °C was added NaIO₄ (1.016 g, 4.75 mmol). The mixture was allowed to slowly warm to 25 °C and stirred for 12 hours. Solid NaHCO₃ was added to the reaction mixture until pH 7. CHCl₃ (16 mL) was added and the mixture was allowed to stir for 5 minutes. The mixture was filtered and the solid was washed with CHCl₃ (6 mL). The combined H₂O/CHCl₃ solution was used directly in the next step without further purification.


Scheme 10

Compound of formula I

To a solution of Compound R (70 mg, 0.1 mmol) in CH₃CN (5 mL) was added sodium cyanoborohydride (50 mg) in water (5 mL). To the above mixture was added a solution of dialdehyde compound 54 (0.6 mmol) in CHCl₃/H₂O (4 mL/ 1 mL). The mixture was stirred for 12 hours, and basified with saturated Na₂CO₃ solution. The mixture was extracted with EtOAc, and organic phase was washed with water and brine, and dried over Na₂SO₄. Purification by reverse-phase HPLC (Phenomenex Synergi® Comb-HTS column) gave the compound of formula I (57 mg).

Method III

Scheme 11



i) TFA, CH_2Cl_2 ; ii) Cmpd 54, NaBH_3CN , $\text{H}_2\text{O}/\text{CH}_3\text{CN}$; iii) LiOH , $\text{THF}/\text{H}_2\text{O}$; iv) cmpd of formula III, DIPEA, EDC, HOBt, THF

Compound 55

Compound 51 (0.28 g, 0.66 mmol) was dissolved in CH_2Cl_2 (4 mL) and TFA (1 mL) was added dropwise. The reaction was allowed to stir at 25 °C for 1 hour. The solvent was removed under reduced pressure to afford compound 55 (0.39 g). m/z : 329.0 ($\text{M}+\text{H}$)⁺.

Compound 56

To a solution of compound 55 (0.39 g, 0.89 mmol) in CH_3CN (45 mL) was added NaBH_3CN (0.45 g, 7.12 mmol) and H_2O (45 mL). A solution of compound 54 (0.55 g, 5.34 mmol) in $\text{CHCl}_3/\text{H}_2\text{O}$ (40 mL) was added. The mixture was stirred at 25 °C for 12 hours. The reaction mixture was made basic with saturated aqueous Na_2CO_3 and extracted sequentially with ethyl acetate and dichloromethane. The combined organic layers were washed sequentially with H_2O

and brine, dried over Na_2SO_4 , filtered, and evaporated. Purification by Combiflash® (stationary phase: silica gel; eluent: 0-10% MeOH/ CH_2Cl_2 gradient) gave compound 56 (0.17 g). m/z : 399.1 ($\text{M}+\text{H}$)⁺.


Compound 57

Compound 56 (377 mg, 0.95 mmol) was dissolved in THF (4 mL) and 1M aqueous LiOH (1.90 mL) was added. The mixture was stirred at 25 °C for 1 hour. The reaction was neutralized with 1M HCl. THF was removed under reduced pressure and the aqueous solution was lyophilized to afford compound 57 (365 mg). The material was used directly in the next step without further purification. m/z : 385.1 ($\text{M}+\text{H}$)⁺.

Compound of formula I

The compound of formula I (185 mg, 57%) was prepared following the same procedure as for compound Q (method I), except that compound 57 (160 mg, 0.42 mmol) was used instead of compound 52. mass m/z : 776.2 ($\text{M}+\text{H}$)⁺.

Method IV



Compound 59

To a solution of compound 122 (33 g, 112 mmol) (prepared by the method of WO2008/010921) in ethanol (366 mL) at 0 °C was added a solution of sodium hydroxide (4.7 g,

117 mmol) in water (62 mL). The mixture was stirred for one hour at 25 °C, and solvents were removed under reduced pressure. The mixture was co-evaporated with ethanol (3x400 mL), and dried at 60 °C for two hours under high vacuum to give a white solid. To the solution of above solid in DMF (180 mL) was added benzyl bromide (16.2 mL, 136 mmol). The mixture was stirred for 16 hours under darkness, and was quenched with water (300 mL). The mixture was extracted with EtOAc (4x300 mL). The combined organic phase was washed with water (5x) and brine, and dried over Na₂SO₄. Concentration gave compound 59 (48 g), which was used in the next step without further purification.

Compound 60

A mixture of compound 59 (33 g, 74 mmol) in DMSO (225 mL) and Et₃N (36 mL) was stirred for 30 minutes. The mixture was cooled to 0-10 °C, SO₃-pyridine (45 g) was added, and the stirring was continued for 60 minutes. Ice (300 g) was added, and the mixture was stirred for 30 minutes. EtOAc (300 mL) was added and sat. Na₂CO₃ was added until pH was 9~10. The organic phase was separated from the aqueous phase, and the aqueous phase was extracted with EtOAc (2x300ml). The combined organic phases were washed with sat Na₂CO₃ (2x), water (3x), and brine. The mixture was dried over Na₂SO₄ and concentrated to give compound 60 (32 g), which was used directly in next step without further purification.

Compound 61

To a solution of compound 60 (32 g) in CH₃CN (325 mL) was added morpholine (12.9 mL, 148 mmol), with a water bath around the reaction vessel, followed by HOAc (8.9 mL, 148 mmol), and NaBH(OAc)₃ (47 g, 222 mmol). The mixture was stirred for 12 hours. CH₃CN was removed under reduced pressure, and the mixture was diluted with EtOAc (300 mL). Sat. Na₂CO₃ was added until the pH was 9~10. The organic phase was separated from the aqueous phase, and the aqueous phase was extracted with EtOAc (2x300 mL). The combined organic phases were washed with sat Na₂CO₃ (2x), water (1x), and brine (1x). The mixture was dried over Na₂SO₄. The resulting residue was concentrated and purified by silica gel column chromatography (EtOAc to DCM/iPrOH =10/1) to give compound 61 (30 g).

Compound 57


To a solution of compound 61 (26.5 g, 56 mmol) in ethanol (160 mL) at 0 °C was added a solution of sodium hydroxide (2.5 g, 62 mmol) in water (30 mL). The mixture was stirred for one hour at 25 °C, and solvents were removed under reduced pressure. The mixture was diluted with water (200 mL), and was washed with CH₂Cl₂ (6x100 mL). The water phase was acidified with 12 N HCl (5.2 mL), and was dried under reduced pressure to give compound 57 (22 g).

Compound of formula I

Compound 57 was converted to the compound of formula I using the procedure described in Method III, above.

The following illustrate non-limiting examples.


Example 1: Preparation of compound 1b (1,6-diphenyl-5S-*tert*-butoxycarbonylamino-3S-hydroxy-2S-phenylmethoxy-carbonylaminohexane).



Benzyl chloroformate (5.1 mL, 36 mmol) was added by addition funnel over approximately 10 minutes to a mechanically stirred mixture of aminoalcohol IV' (11.54 g, 30 mmol) and pyridine (2.94 mL, 36 mmol) in dichloromethane (200 mL) at 0 °C. The cooling bath was removed and the reaction was allowed to warm to room temperature and stirred overnight. At the end of this period, HPLC analysis showed the presence of <3A% of the starting alcohol IV'. The reaction mixture was filtered and the white residue (amino alcohol IV') was washed with dichloromethane (100 mL). The filtrate was transferred to a separatory funnel. The organic layer was washed twice with cold (0 °C) 5% sodium bisulfate solution (2 x 75 mL), twice with saturated sodium bicarbonate solution (2 x 100 mL), brine (100 mL) and dried over anhydrous sodium sulfate. Removal of the solvent *in vacuo* afforded a white solid which was triturated with hexane and filtered. The carbamate 1b was obtained as white solid weighing 13.22 g (85%). Thin layer chromatography (Tlc) assay showed R_f = 0.19 on SiO₂ using 25% ethyl acetate/hexane as the eluent or an R_f = 0.75 on SiO₂ using 50% ethyl acetate/hexane as the eluent. ¹H NMR (300 MHz,


CDCl₃): δ 7.4-7.05 (m, 15H), 5.09 (m, 1H), 5.05 (s, 2H), 4.5 (br s, 1H), 3.88-3.74 (m, 2H), 3.63 (br s, 1H), 2.87-2.85 (d, 2H, J=7.8 Hz), 2.72-2.70 (d, 2H, J=6.3 Hz), 1.63-1.60 (m, 2H), 1.38 (s, 9H).

Example 2: Preparation of compound 2b (3S-dithiocarbonic acid 1,6-diphenyl-5S-*tert*-butoxycarbonylamino-2S-phenylmethoxycarbonylaminohexane, methyl ester).




Sodium hydride (160 mg, 4 mmol, 60% oil dispersion) was added to a magnetically stirred solution of the carbamate 1b (2.07 g, 4 mmol) in THF (30 mL) at room temperature. A vigorous gas evolution occurred. The reaction was stirred at room temperature for 30 minutes and then carbon disulfide (724 μ L, 12 mmol) was added in one portion. The reaction was stirred for 1 hour to afford a yellow solution. Methyl iodide (274 μ L, 4.4 mmol) was then added and the reaction and allowed to stir overnight. At the end of this period, the reaction was judged complete and the mixture was transferred to a round-bottom flask and the solvent was removed in vacuo. The residue was transferred to a separatory funnel with ethyl acetate (300 mL) and pH 6 phosphate buffer (100 mL). After mixing, the layers were separated. The aqueous layer was re-extracted with ethyl acetate (100 mL). The combined organic extracts were washed with brine and dried over anhydrous sodium sulfate. Removal of the solvent *in vacuo* afforded a thick residue. The residue was adsorbed onto 20 mL of silica gel with MTBE. The residue was chromatographed on 80 mL of flash silica gel using a hexane to 30% ethyl acetate/hexane gradient to afford 1.79 g (74%) of the desired xanthate 2b. Tlc assay showed R_f = 0.64 on SiO₂ using 25% ethyl acetate/hexane as the eluent. ¹H NMR (300 MHz, CDCl₃): δ 7.4-7.0 (m, 15H), 5.83-5.79 (t, 1H, J=6.3 Hz), 5.05-4.9 (q, 2H, J=12 Hz), 4.85-4.82 (m, 1H), 4.55-4.2 (m, 2H), 4.08-4.01 (br s, 1H), 2.84-2.6 (m, 4H), 2.56 (s, 3H), 1.8 (br s, 2H), 1.38 (s, 9H).

Example 3: Preparation of compound 3b (3S-imidazolecarbothioic acid 1,6-diphenyl-5S-*tert*-butoxycarbonylamino-2S-phenyl methoxycarbonylaminohexane, ester).



Thiocarbonyldiimidazole (TCDI) (2.14 g, 12 mmol) was added to a magnetically stirred solution of alcohol 1b (3.11 g, 6 mmol) and imidazole (408 mg, 6 mmol) in THF (30 mL) at room temperature. The reaction mixture was stirred for 48 hours and judged complete by HPLC analysis. The reaction mixture was transferred to a round-bottom flask and the solvent was removed *in vacuo*. The residue was dissolved in ethyl acetate (200 mL) and transferred to a separatory funnel. The organic layer was washed twice with cold (0 °C) 5% sodium bisulfate solution (2 x 100 mL), saturated sodium bicarbonate solution (100 mL), brine (100 mL) and dried over anhydrous sodium sulfate. Filtration and removal of the solvent *in vacuo* afforded 4.1 g crude semisolid. The crude solid was adsorbed onto 24 mL of flash silica gel and chromatographed on 82 mL of flash silica gel using a 20% ethyl acetate/hexane to 60% ethyl acetate/hexane gradient. The imidazolide 3b product (Im is imidazol-1-yl) was obtained in 3.5 g (93%) as a white solid foam. Tlc assay showed $R_f = 0.28$ on SiO_2 using 25% ethyl acetate/hexane as the eluent or $R_f = 0.80$ on SiO_2 using 50% ethyl acetate/hexane as the eluent.


Example 4: Preparation of compound 4b (1,6-diphenyl-5R-*tert*-butoxycarbonylamino- 2R-phenylmethoxycarbonylamino-hexane).



A solution of xanthate 2b (243 mg, 0.4 mmol) and benzoyl peroxide (97 mg, 0.4 mmol) in dioxane (4 mL) was added over two hours *via* a syringe pump to a magnetically stirred, deoxygenated mixture of dioxane (8 mL) and 1-ethylpiperidine hypophosphite (3.6 g, 20 mmol) at 105 °C. After the addition was complete, the reaction mixture was heated at 105 °C for two additional hours. The reaction was cooled and judged to be complete by HPLC analysis. The reaction mixture was poured over saturated sodium bicarbonate solution (50 mL) and extracted

twice with ethyl acetate (50 mL). The combined organic extracts were washed with brine and dried over anhydrous sodium sulfate. Removal of the solvent *in vacuo* afforded a thick oil. The oil was chromatographed on silica gel (20 mL) with a gradient of 100% hexane to 40% ethyl acetate/hexane to afford 200 mg (100%) of a white solid (94A% pure). The white solid was recrystallized from hexane/MTBE (1:5, 15 mL). The product 4b was obtained in 160 mg (80% yield) in >99A% purity. Tlc assay showed $R_f = 0.61$ on SiO_2 using 25% ethyl acetate/hexane as the eluent. $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 7.4-7.1 (m, 15H), 5.049 (s, 2H), 4.48 (d, 1H, $J=8.7$ Hz), 4.21 (br d, 1H), 3.92-3.7 (br m, 2H), 2.8-2.6 (m, 4H), 1.6-1.4 (br s, 2H), 1.38 (s, 9H).


Example 5: Preparation of compound 4b (1,6-diphenyl-5R-*tert*-butoxycarbonylamino-2R-phenylmethoxycarbonylamino- hexane).



A magnetically stirred solution of the thionoimidazolidine 3b (2.02 g, 3.2 mmol) and dimethyl phosphite (14.7 mL, 160 mmol) in dioxane (32 mL) was heated to 105 °C. A solution of benzoyl peroxide (465 mg, 1.92 mmol) in dioxane (2.3 mL) was added to the heated solution over 6 hours via syringe pump. After the addition was complete, the reaction was heated at 105 °C for an additional two hours and then allowed to cool overnight. At the end of this period, the reaction was analyzed by HPLC and found to be complete. The reaction mixture was poured over cold (0 °C) saturated sodium bicarbonate solution. Some precipitate formed. The quenched reaction mixture was transferred to a separatory funnel and extracted twice with ethyl acetate (2 x 250 mL). The combined organic extracts were washed twice with water (2 x 200 mL), brine (200 mL) and dried over anhydrous sodium sulfate. The solvent was removed *in vacuo* to afford 2.2 g crude semi-solid. The crude material was adsorbed onto flash silica gel (14 mL) and chromatographed on flash silica gel using a 100% hexane to 30% ethyl acetate/hexane gradient. Compound 4b was obtained as a white solid weighing 1.28 g (80%) at approximately 80% purity by HPLC. Recrystallization of the solid with MTBE/hexane (5:1, 65 mL) afforded 1.04 g (65%) of 4b in >99% purity. Tlc assay showed $R_f = 0.61$ on SiO_2 using 25% ethyl acetate/hexane as the eluent. $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 7.4-7.1 (m, 15H), 5.042 (s, 2H), 4.56 (br d, 1H, $J=7.8$ Hz),


4.28 (br d, 1H, J=9 Hz), 3.92-3.7 (br m, 2H), 2.8-2.6 (m, 4H), 1.6-1.4 (br s, 2H), 1.38 (s, 9H).

Example 6: Preparation of compound V' (1,6-diphenyl-5S-*tert*-butoxycarbonylamino-3S-hydroxy-2S-(5-thiazolemethoxy) carbonylaminohexane).



To a magnetically stirred mixture of amino alcohol IV' (3.84 g, 10 mmol) in acetonitrile (100 mL) at room temperature, was added ((5-thiazole)methyl)-4-nitrophenyl carbonate (3.08 g, 11 mmol). The reaction mixture was stirred for approximately 20 minutes and then was added diisopropylethylamine (2 mL, 11 mmol). The reaction was allowed to stir at room temperature for 48 hours. At this point, the reaction was analyzed by HPLC and judged to be complete. The reaction mixture was transferred to a round-bottom flask and the solvent was removed *in vacuo*. The residue was dissolved in ethyl acetate and transferred to a separatory funnel. The reaction mixture was washed twice with cold (0 °C) 5% sodium bisulfate solution (2 x 75 mL), twice with 1M sodium carbonate solution (2 x 100 mL), brine (100 mL) and dried over anhydrous sodium sulfate. The solvent was removed *in vacuo* to afford 6 g of crude material. The residue was chromatographed on silica gel (100 mL) using a 20% ethyl acetate/hexane to 60% ethyl acetate/hexane gradient to obtain 4.97 g (94%) of the desired carbamate V' as a white solid. Tlc assay showed $R_f = 0.32$ on SiO_2 using 50% ethyl acetate/hexane as the eluent. ^1H NMR (300 MHz, CDCl_3): δ 8.79 (s, 1H), 7.84 (s, 1H), 7.35-7.05 (m, 15H), 5.24 (s, 2H), 5.12 (d, 1H, J=9.3 Hz), 4.50 (br s, 1H), 3.9-3.7 (m, 2H), 3.64 (br s, 1H), 2.85 (d, 2H, J=7.5 Hz), 2.73 (d, 2H, J=6.6 Hz), 1.62 (br s, 2H), 1.39 (s, 9H).


Example 7: Preparation of compound 7b (3S-imidazolecarbothioic acid 1,6-diphenyl-5S-*tert*-butoxycarbonylamino-2S-(5-thiazolemethoxycarbonylamino)hexane, ester).



Thiocarbonyldiimidazole (TCDI) (1.07 g, 6 mmol) was added to a magnetically stirred solution of alcohol V' (1.58 g, 3 mmol) and imidazole (204 mg, 3 mmol) in THF (20 mL) at room temperature. The reaction mixture was stirred for 48 hours and then determined complete by HPLC. The reaction mixture was transferred to a round-bottom flask and the solvent was removed *in vacuo*. The residue was dissolved in ethyl acetate (200 mL) and transferred to a separatory funnel. The organic layer was washed twice with cold (0 °C) 5% sodium bisulfate solution (2 x 50 mL), saturated sodium bicarbonate solution (100 mL), brine (100 mL) and dried over anhydrous sodium sulfate. The solvent was removed *in vacuo* and the solids were filtered to afford 2.2 g crude product. The crude solid was adsorbed onto 14 mL of flash silica gel and chromatographed on 40 mL of flash silica gel using a 20% ethyl acetate/hexane to 60% ethyl acetate/hexane gradient to afford 1.9 g (>99%) of imidazolide 7b (Im is imidazol-1-yl) as a white solid foam in 97A% purity. Tlc assay showed $R_f = 0.32$ on SiO_2 using 50% ethyl acetate/hexane as the eluent.

^1H NMR (300 MHz, CDCl_3): δ 8.77 (s, 1H), 8.22 (s, 1H), 7.80 (s, 1H), 7.52 (s, 1H), 7.35-7.1 (m, 15H), 7.03 (s, 1H), 5.77 (m, 1H), 5.18 (q, 2H, $J=9$ Hz), 4.74 (m, 1H), 4.62 (br s, 1H), 4.45 (m, 1H), 4.2-4.1 (br s, 1H), 2.95-2.6 (m, 4H), 2.0-1.8 (br s, 2H), 1.38 (s, 9H).


Example 8: Preparation of compound 6 (1,6-diphenyl-5S-*tert*-butoxycarbonylamino-2S-(5-thiazolemethoxy)carbonylamino-hexane).



A solution of xanthate 7b (64 mg, 0.1 mmol) and benzoyl peroxide (18 mg, 0.075 mmol) in dioxane (1.5 mL) was added *via* a syringe pump to a magnetically stirred and deoxygenated


mixture of dioxane (3 mL) and 1-ethylpiperidine hypophosphite (900 mg, 5 mmol) at 105 °C over two hours. After the addition was complete, the reaction mixture was heated at 105 °C for two additional hours. The reaction was cooled and judged complete by HPLC analysis. The isolated product mixture contained alcohol V' and compound 6 in a ratio 2:1.

Example 9: Preparation of compound 13 (2R-(2S-t-butoxycarbonylamino-3-phenylpropyl)-3S-benzylaziridine).



Diisopropyl diazodicarboxylate (17.3 mL, 88 mmol) was added to a mechanically stirred solution of triphenylphosphine (23.1 g, 88 mmol) in toluene (300 mL) at 5 °C. The temperature was not allowed to rise above 10 °C during the addition. The solution was cooled back to 5 °C and then aminoalcohol IV' (30.76 g, 80 mmol) was added portionwise over approximately 10 minutes. The cooling bath was removed and the resulting suspension was allowed to stir for 48 hours. The reaction was filtered, washed with 150 mL of cold (0 °C) toluene, and dried afford 35 g of the white solid. The white solid was recrystallized from a mixture of 130 mL of methanol and 88 mL of water to afford 18.7 grams (63%) of 13. The recrystallization mother liquors and the filtrate were added together and concentrated *in vacuo* to afford 43 g of a yellow semi-solid. The residue was stirred with 400 mL of a 1:1 mixture of methanol and water overnight to form a white solid (37 g). This material was chromatographed on C-18 reverse-phase silica gel (1200 g) using a 50% methanol/water to 90% methanol/water gradient. The fractions containing the product were combined and the solvent was removed *in vacuo* to give 13 as a white solid (2.9 g, 10%). The combined total of the two crops of aziridine 13 was 21.6 g (73%). ¹H NMR (300 MHz, CD₃OD): δ 7.35-7.15 (m, 10H), 4.0-3.85 (br s, 1H), 2.90-2.6 (m, 4H), 2.35-2.15 (m, 2H), 1.75-1.5 (m, 2H), 1.35 (s, 9H).


Example 10: Preparation of compound 9b (3S-toluene-4-sulfonic acid 1,6-Diphenyl-5S-*tert*-butoxycarbonylamino-2S-phenyl methoxycarbonylamino-hexane, ester).



p-Toluenesulfonyl chloride (19.5 g, 102 mmol) was added in one portion to a solution of carbamate 1b (26.5 g, 51 mmol) dissolved in pyridine (80 mL) at room temperature. A slight exotherm ($\sim 5^\circ\text{C}$) was noted. The reaction was stirred overnight at room temperature overnight. At the end of this period, the reaction was judged complete by tlc assay. The reaction mixture was poured into water (500 mL) and extracted with 20% ethyl acetate/hexane (1 L). The organic layer was washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was azeotroped with toluene, but after the concentration was complete, the residue still contained some pyridine. The residue was adsorbed onto 200 mL of silica gel with ethyl acetate. After removal of the ethyl acetate, hexane was added to the silica gel. Removal of the hexane afforded free-flowing silica which was loaded on top of a silica gel pad (400 mL). The silica plug was rinsed with hexane (2 L), 10% ethyl acetate/hexane (4 L) and 20% ethyl acetate/hexane (4 L). The product eluted with 20% ethyl acetate/hexane. Combination of the product containing fractions and removal of the solvent *in vacuo* afforded 25.4 g (74% yield) of the desired tosylate 9b as a white solid. Tlc assay showed $R_f = 0.54$ on SiO_2 using 25% ethyl acetate/hexane as the eluent. ^1H NMR (300 MHz, CDCl_3): δ 7.77-7.74 (d, 2H), 7.4-7.0 (m, 19H), 5.0-4.8 (m, 2H), 4.74-4.66 (m, 1H), 4.63-4.60 (m, 1H), 4.42 (br s, 1H), 4.2-4.1 (m, 1H), 4.0 (br s, 1H), 2.65-2.35 (m, 4H), 2.42 (s, 3H), 1.66 (br s, 2H), 1.42 (s, 9H).

Example 11: Preparation of compound 10b (3S-toluene-4-sulfonic acid

1,6-Diphenyl-5S-amino-2S-phenylmethoxycarbonyl amino hexane, ester).




Dichloromethane (50 mL) was added to a 125 mL three-necked flask containing tosylate 9b (6.73 g, 10 mmol). The reaction mixture was cooled to -20°C . Trifluoroacetic acid (20 mL, 260 mmol) was added dropwise *via* addition funnel over 5 minutes and the resulting mixture was stirred at -20°C for 10 minutes and then allowed to warm to room temperature and stir for 45

minutes. Analysis by HPLC at this point indicated that the reaction was complete.


A mixture of 1.2M (10%) solution of sodium bicarbonate (420 mL) and ice (100 g) was prepared. The reaction mixture was poured slowly (foaming) into the rapidly stirred mixture of ice and sodium bicarbonate solution. When all of the reaction mixture had been added, the pH of the mixture was approximately 8. The two-phase mixture was then poured into a separatory funnel. The layers were separated. The aqueous phase was washed twice with dichloromethane (2 x 100 mL). The combined organic phases were dried over anhydrous sodium sulfate. Removal of the solvent *in vacuo* afforded 5.8 g (100%) of tosylate 10b as a solid foam. Tlc assay showed $R_f = 0.32$ on SiO_2 using 50% ethyl acetate/hexane as the eluent. $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 7.85-7.75 (m, 2H), 7.4-7.0 (m, 19H), 5.03-4.8 (m, 2H), 5.1-4.8 (br d, 1H), 3.2-2.8 (m, 2H), 2.8-2.5 (m, 2H), 2.42 (s, 3H).

Example 12: Preparation of compound 11b (2R-(2S-amino-3-phenylpropyl)-3S-benzylaziridine-1-carboxylic acid benzyl ester).



A 1M potassium t-butoxide solution in THF (7.4 mL, 7.4 mmol) was added to a solution of amino tosylate 10b (4.0 g, 7 mmol) in tetrahydrofuran (50 mL) at $-20\text{ }^\circ\text{C}$. During the addition, an exotherm of $2\text{-}3\text{ }^\circ\text{C}$ was noted. After the addition was complete, the reaction mixture was allowed to warm to $0\text{ }^\circ\text{C}$. TLC and HPLC indicated that the reaction was complete. The reaction mixture was poured into 200 mL of pH 6 phosphate buffer to quench the reaction. This mixture was then transferred to a separatory funnel and extracted with ethyl acetate (2 x 150 mL). The combined organic extracts were washed with brine (2 x 100 mL) and dried over anhydrous sodium sulfate. Filtration and removal of the solvent *in vacuo* afforded 2.91 g ($>100\%$) of the desired material as a thick liquid. The crude material was chromatographed on silica gel using a 40% ethyl acetate/hexane to 100% ethyl acetate gradient. The aziridine 11b (2.58 g, 92% yield) was obtained as a sticky white solid. Tlc assay showed $R_f = 0.25$ on SiO_2 using 50% ethyl acetate/hexane as the eluent. $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 7.4-7.1 (m, 15H), 5.15-5.0 (q, 2H, $J=5.7\text{ Hz}$), 3.4-3.25 (br s, 1H), 3.0-2.85 (m, 2H), 2.85-2.65 (m, 2H), 1.8-1.55 (m, 2H), 1.7-1.5 (br s, 2H).


Example 13: Preparation of compound 12 (1,6-diphenyl-2R-(t-butoxycarbonyl)amino-5R-carbamic acid, t-butyl ester) and compound 12a (1,6-diphenyl-2R-(t-butoxycarbonyl)amino-4S-carbamic acid, t-butyl ester).



The aziridine 11b (400 mg, 1 mmol), 10% palladium on carbon (50% water wet) (200 mg) and absolute ethanol (20 mL) were added to a pressure vessel equipped with a stirring bar. The vessel was capped and three vacuum purges with nitrogen were performed. Then two vacuum purges with hydrogen were performed. The pressure of hydrogen was then regulated at 50 psi and the reaction was allowed to stir overnight. In the morning, the reaction was analyzed by HPLC. The starting material had been consumed and converted to two products. The reaction mixture was filtered through a pad of celite. The celite pad was washed thoroughly with ethanol. Removal of the solvent *in vacuo* afforded 268 mg (100%) of a clear oil.

The clear oil (268 mg, 1 mmol) was dissolved in THF (5 mL). Di-*t*-butyl dicarbonate (655 mg, 3 mmol) and diisopropylethylamine (523 μ L, 3 mmol) were added to the reaction. The reaction was allowed to stir for 48 hours. HPLC of the reaction indicated that the reaction was complete. The solvent was removed and the residue was chromatographed on silica gel (40 mL) using a hexane to 30% ethyl acetate/hexane gradient. Two components were obtained. The first component was identified as 12a and weighed 99 mg (21% yield) (tlc assay showed $R_f = 0.30$ on SiO_2 , 10% ethyl acetate/hexane). ^1H NMR (400 MHz, CDCl_3): δ 7.4-7.15 (m, 10H), 4.7-4.6 (br s, 1H), 4.6-4.5 (br s, 1H), 3.8-3.9 (br s, 1H), 3.6-3.75 (br s, 1H), 3.0-2.5 (m, 6H), 1.6-1.4 (br s, 2H), 1.42 (s, 9H), 1.37 (s, 9H). The second component was identified as 12 and weighed 255 mg (54% yield) (tlc assay showed $R_f = 0.24$ on SiO_2 , 10% ethyl acetate/hexane). ^1H NMR (400 MHz, CDCl_3): δ 7.35-7.15 (m, 10H), 4.28 (d, 2H, $J=8$ Hz), 3.9-3.75 (br m, 2H), 2.8-2.6 (m, 4H), 1.6-1.4 (m, 2H), 1.41 (s, 18H).

Example 14: Preparation of compound 12a (1,6-diphenyl-2R,5R-diaminohexane dihydrochloride).



10% Palladium on carbon (50 mg) was added to a 40:60 mixture of 4a' and 4b (285 mg, 0.57 mmol) in ethanol (25 mL) in a thick-walled hydrogenation vessel equipped with a stirring bar. Three cycles of vacuum purges with nitrogen followed by three vacuum purges with hydrogen were performed. The internal hydrogen pressure was set at 50 psi and the reaction was allowed to stir at room temperature for 48 hours. At the end of this time, the reaction was analyzed by HPLC and found to be complete. The reaction was filtered through a pad of celite. The celite pad was thoroughly washed with ethanol (25 mL). The solvent was removed *in vacuo* to afford 223 mg (~100%) of a clear oil. The oil was chromatographed on silica gel to afford 150 mg (73% yield) of 5 as a thick oil which solidified on standing.

Compound 5 (100 mg, 0.27 mmol) was added to 5M HCl in isopropanol (3 mL). A solution formed after approximately 10 minutes and after 30 minutes, a fine, white precipitate started to come out of solution. The reaction was allowed to stir at room temperature overnight. At the end of this period, the reaction was judged complete by HPLC analysis. An aliquot (1 mL) was removed from the reaction and the solvent was removed with a nitrogen sparge. A white solid formed. Sodium hydroxide (3 mL of a 1N NaOH solution) was added to the solid. An organic liquid separated which was partitioned into MTBE. The MTBE solution was separated and blown down with a nitrogen sparge. Compound II (free base of IIa) (19 mg, 28% yield) was obtained as a clear thick oil after the solvent was removed.

The remainder of the isopropanol/HCl mixture was diluted with diethyl ether (10 mL). The resulting mixture was cooled to -78 °C in a dry-ice bath and filtered. The white solid was washed with diethyl ether (10 mL) and dried in a vacuum oven (no heat) at 25 mm Hg vacuum. Compound IIa (50 mg, 54% yield) was obtained as a white solid.

HPLC analysis of the 50 mg sample of IIa salt and 19 mg of II from the deprotection of 5


with HCl in isopropanol was performed. The diastereomeric excess of the IIa was >99%. The diastereomeric excess of II was 96.3%.

All publications, patents, and patent documents are incorporated by reference herein, as though individually incorporated by reference. Various embodiments and techniques have been described. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the disclosure.

CLAIMS

What is claimed is:

1. A compound selected from:



wherein:

R^{1a} and R^{1b} are each independently an amine protecting group; or R^{1a} is an amine protecting group and R^{1b} is H;


R^{1c} is $-C(O)O(C_1-C_6)$ alkyl wherein $-C(O)O(C_1-C_6)$ alkyl is optionally substituted with one or more halogen or (C_1-C_6) alkoxy;

R^2 is $-SMe$ or imidazol-1-yl; and


R^4 is $-SO_2(C_1-C_6)$ alkyl or $-SO_2$ aryl, wherein $-SO_2(C_1-C_6)$ alkyl is optionally substituted with one or more halogen, and wherein $-SO_2$ aryl is optionally substituted with one or more halogen, (C_1-C_6) alkyl or NO_2 ;

and salts thereof;

provided the compound is not:



2. The compound of claim 1 selected from:




and salts thereof.

3. The compound of claim 1 or claim 2, wherein R^{1a} and R^{1b} are each independently $-\text{C(O)O-CH}_2\text{Ph}$, $-\text{C(O)O}(\text{C}_1\text{-C}_6)\text{alkyl}$ or Ph-CH_2- ; or R^{1a} is $-\text{C(O)O-CH}_2\text{Ph}$, $-\text{C(O)O}(\text{C}_1\text{-C}_6)\text{alkyl}$ or Ph-CH_2- and R^{1b} is H; wherein any $\text{C(O)O-CH}_2\text{Ph}$, $-\text{C(O)O}(\text{C}_1\text{-C}_6)\text{alkyl}$ or Ph-CH_2- of R^{1a} and R^{1b} is optionally substituted with one or more $(\text{C}_1\text{-C}_6)\text{alkyl}$ or $(\text{C}_1\text{-C}_6)\text{alkoxy}$.


4. The compound of claim 1 or claim 2, wherein R^{1a} is $-\text{C(O)O-CH}_2\text{Ph}$ and R^{1b} is H; wherein any $-\text{C(O)O-CH}_2\text{Ph}$ of R^{1a} is optionally substituted with one or more $(\text{C}_1\text{-C}_6)\text{alkyl}$ or $(\text{C}_1\text{-C}_6)\text{alkoxy}$.

5. The compound of claim 1 selected from:




and salts thereof.

6. The compound of claim 1, comprising:




or a salt thereof.

7. The compound of claim 1, comprising:




or a salt thereof.

8. The compound of claim 1, comprising:




or a salt thereof.

9. The compound of claim 1, comprising:




or a salt thereof.

10. The compound of claim 1, comprising:




or a salt thereof.

11. The compound of claim 1, comprising:




or a salt thereof.

12. The compound of claim 1, comprising:




or a salt thereof.

13. The compound of claim 1, comprising:




or a salt thereof.

14. The compound of claim 1, comprising:




or a salt thereof.

15. The compound of claim 1, comprising:




or a salt thereof.

16. A method for preparing a compound of formula I:



or a salt thereof, comprising converting a compound of claim 1.

17. The method of claim 16 further comprising converting the compound of claim 1 into a compound of formula III:



or a salt thereof.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2013/024431

A. CLASSIFICATION OF SUBJECT MATTER					
INV. C07C271/12	C07C271/16	C07C271/20	C07D203/20	C07D233/60	
C07D277/24	C07D417/12	C07C309/73	C07C329/16	A61K31/426	
A61P31/12					
According to International Patent Classification (IPC) or to both national classification and IPC					

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols) C07C C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CN 101 967 130 A (XIAMEN HENRY BIOLOG CHEMISTRY CO LTD) 9 February 2011 (2011-02-09) paragraph [0032] - paragraph [0033]; compound III & DATABASE WPI Section Ch, Week 201140 Thomson Scientific, London, GB; Class B07, AN 2011-D34863 & CN 101 967 130 A (XIAMEN HENRYBIOCHEM CO LTD) 9 February 2011 (2011-02-09) abstract <div style="text-align: center; margin-top: 10px;">----- -/--</div>	1-3

Further documents are listed in the continuation of Box C.
 See patent family annex.

* Special categories of cited documents :

<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>
---	---

Date of the actual completion of the international search	Date of mailing of the international search report
26 March 2013	03/07/2013

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Ginoux, Claude
--	--

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2013/024431

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>RAMU E ET AL: "A short approach to the synthesis of the ritonavir and lopinavir core and its C-3 epimer via cross metathesis", TETRAHEDRON ASYMMETRY, PERGAMON PRESS LTD, OXFORD, GB, vol. 20, no. 19, 6 October 2009 (2009-10-06), pages 2201-2204, XP026733441, ISSN: 0957-4166, DOI: 10.1016/J.TETASY.2009.09.003 [retrieved on 2009-10-14] paragraph [04.3]; compound 3</p>	1-3
X	<p>GHOSH A K ET AL: "POTENT HIV-1 PROTEASE INHIBITORS: STEREOSELECTIVE SYNTHESIS OF A DIPEPTIDE MIMIC", JOURNAL OF ORGANIC CHEMISTRY, ACS, US, vol. 58, no. 5, 26 February 1993 (1993-02-26), pages 1025-1029, XP000577046, ISSN: 0022-3263, DOI: 10.1021/J000057A011 page 1028, right-hand column, last paragraph; compound 13</p>	1-3
X	<p>GURJAR M K ET AL: "Synthesis of novel C2-symmetric and pseudo C2-symmetric based diols, epoxides and dideoxy derivatives of HIV protease inhibitors", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 53, no. 13, 31 March 1997 (1997-03-31), pages 4769-4778, XP004771898, ISSN: 0040-4020, DOI: 10.1016/S0040-4020(97)00160-9 Scheme 4; compound 26</p>	1-3
X	<p>WO 94/14436 A1 (ABBOTT LAB [US]) 7 July 1994 (1994-07-07) cited in the application examples 67A, 68C</p>	1-3
A	<p>WO 2010/115000 A2 (GILEAD SCIENCES INC [US]; POLNIASZEK RICHARD [US]; PFEIFFER STEVEN [US]) 7 October 2010 (2010-10-07) cited in the application claims 4,9,15-19,79; examples 6,7</p>	1-10, 13-17
A	<p>WO 2008/010921 A2 (GILEAD SCIENCES INC [US]; DESAI MANOJ C [US]; HONG ALLEN YU [US]; LIU) 24 January 2008 (2008-01-24) cited in the application Scheme 8, page 189</p>	1-10, 13-17

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2013/024431

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

3, 4, 6-10, 13-15(completely); 1, 2, 5, 16, 17(partially)

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 3, 4, 6-10, 13-15(completely); 1, 2, 5, 16, 17(partially)

Compounds according to the formulae of claim 1 identified in the description as 1a, 2a' (2a and 3a), 4, 4a, 9a, 10a and 11a, i.e. the first four and the last three formulae of claim 1; compounds of the corresponding formulae of claim 2; compounds according to claims 3 and 4; The first five and the last three compounds of claim 5; the compounds of claims 6-10 and 13-15; the method of claims 16 and 17 as far as it refers to the previous compounds.

2. claims: 11, 12(completely); 1, 2, 5, 16, 17(partially)

Compounds according to the formulae of claim 1 identified in the description as 6 and 7a, i.e. the fifth and sixth formulae of claim 1; compounds of the corresponding formulae of claim 2; The sixth and seventh compounds of claim 5; the compounds of claims 11 and 12; the method of claims 16 and 17 as far as it refers to the previous compounds.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2013/024431

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
CN 101967130	A	09-02-2011	NONE

WO 9414436	A1	07-07-1994	AT 143262 T 15-10-1996
			AT 213733 T 15-03-2002
			AT 230402 T 15-01-2003
			AT 417836 T 15-01-2009
			AU 659575 B2 18-05-1995
			AU 677500 B2 24-04-1997
			AU 697681 B2 15-10-1998
			CA 2135890 A1 07-07-1994
			CA 2170020 A1 30-06-1994
			CA 2502856 A1 30-06-1994
			CA 2585898 A1 30-06-1994
			CA 2605872 A1 30-06-1994
			DE 674513 T1 18-01-1996
			DE 10199053 I1 29-08-2002
			DE 69305093 D1 31-10-1996
			DE 69305093 T2 17-04-1997
			DE 69331643 D1 04-04-2002
			DE 69331643 T2 31-10-2002
			DE 69332616 D1 06-02-2003
			DE 69332616 T2 06-11-2003
			DK 0674513 T3 17-03-1997
			DK 0727419 T3 10-06-2002
			DK 1090914 T3 22-04-2003
			DK 1302468 T3 02-03-2009
			EP 0674513 A1 04-10-1995
			EP 0727419 A2 21-08-1996
			EP 1090914 A2 11-04-2001
			EP 1302468 A1 16-04-2003
			ES 2088839 T1 01-10-1996
			ES 2174992 T3 16-11-2002
			ES 2189721 T3 16-07-2003
			ES 2317977 T3 01-05-2009
			GR 3021170 T3 31-12-1996
			GR 95300059 T1 30-11-1995
			HK 130697 A 26-09-1997
			HK 1039612 A1 24-10-2003
			HK 1057038 A1 10-07-2009
			HU 211606 A9 28-12-1995
			IL 108126 A 30-03-1995
			IL 112962 A 28-09-2000
			IL 136396 A 29-12-2008
			JP 2637847 B2 06-08-1997
			JP 2761374 B2 04-06-1998
			JP 3812969 B2 23-08-2006
			JP 3914065 B2 16-05-2007
			JP H1087639 A 07-04-1998
			JP H08505844 A 25-06-1996
			JP H09118679 A 06-05-1997
			JP 2002322159 A 08-11-2002
			JP 2006232845 A 07-09-2006
			JP 2010215650 A 30-09-2010
			LU 90839 I2 19-11-2001
			NL 300060 I1 01-12-2001
			PT 727419 E 30-08-2002
			PT 1302468 E 13-02-2009
			US 5846987 A 08-12-1998

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2013/024431

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		US 5886036 A	23-03-1999
		US 6017928 A	25-01-2000
		US 6150530 A	21-11-2000
		US 6531610 B1	11-03-2003
		US 2003195362 A1	16-10-2003
		WO 9414436 A1	07-07-1994

WO 2010115000	A2	07-10-2010	
		AR 076027 A1	11-05-2011
		AU 2010232559 A1	06-10-2011
		CA 2754698 A1	07-10-2010
		CN 102438982 A	02-05-2012
		CO 6400216 A2	15-03-2012
		EA 201190179 A1	30-01-2013
		EP 2414325 A2	08-02-2012
		JP 2012522797 A	27-09-2012
		KR 20120006035 A	17-01-2012
		PE 06172012 A1	26-05-2012
		SG 174585 A1	28-10-2011
		TW 201100412 A	01-01-2011
		US 2010256366 A1	07-10-2010
		UY 32535 A	29-10-2010
		WO 2010115000 A2	07-10-2010

WO 2008010921	A2	24-01-2008	
		AR 061838 A1	24-09-2008
		AU 2007275860 A1	24-01-2008
		BR PI0714055 A2	18-12-2012
		CA 2653374 A1	24-01-2008
		CN 101490023 A	22-07-2009
		EA 200900155 A1	30-06-2009
		EP 2049506 A2	22-04-2009
		EP 2487165 A1	15-08-2012
		HR P20090077 A2	30-06-2009
		JP 4881433 B2	22-02-2012
		JP 2009542696 A	03-12-2009
		JP 2012051933 A	15-03-2012
		KR 20090028821 A	19-03-2009
		NZ 573060 A	24-02-2012
		SG 183007 A1	30-08-2012
		TW 200811167 A	01-03-2008
		US 2008108617 A1	08-05-2008
		US 2009291952 A1	26-11-2009
		US 2011212964 A1	01-09-2011
		US 2013123311 A1	16-05-2013
		WO 2008010921 A2	24-01-2008
